

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

F1_Rev.1_M3

NTP Study Number: C20209
Lock Date: 08/31/2011
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 3.0.2.2_002
PWG Approval Date: NONE

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF PENTABROMODIPHENYL OXIDE (TECHNICAL) (DE 71)

MALE MICE

Organ

Adrenal Cortex

Adrenal Cortex: Capsule

Epididymis

Heart

Islets, Pancreatic

Kidney

Kidney: Papilla

Kidney: Renal Tubule

Liver

Liver: Hepatocyte, Centrilobular

Liver: Kupffer Cell

Lung

Lung: Alveolar Epithelium

Lymph Node, Mesenteric

Mesentery: Artery

Nose

Pancreas

Morphology

Accessory Adrenal Cortical Nodule

Hypertrophy Diffuse

Hypertrophy Focal

Hyperplasia

Inflammation Chronic

Cardiomyopathy

Mineralization

Hyperplasia

Infiltration Cellular Mononuclear Cell

Mineralization

Nephropathy

Necrosis

Degeneration

Basophilic Focus

Clear Cell Focus

Eosinophilic Focus

Fatty Change

Hematopoietic Cell Proliferation

Inflammation Chronic

Necrosis Focal

Hypertrophy

Pigmentation

Hemorrhage

Infiltration Cellular Histiocyte

Thrombosis

Hyperplasia

Atrophy

Hemorrhage

Pigmentation

Inflammation Chronic

Inflammation Acute

Atrophy

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF PENTABROMODIPHENYL OXIDE (TECHNICAL) (DE 71)

Pituitary Gland: Pars Distalis	Inflammation Chronic
Preputial Gland	Hyperplasia Focal
	Cyst
Prostate	Inflammation Chronic
Prostate: Epithelium	Inflammation Chronic
Salivary Glands	Hyperplasia
	Infiltration Cellular Mononuclear Cell
	Mineralization
Seminal Vesicle	Inflammation Chronic
Skeletal Muscle	Fibrosis
	Hemorrhage
	Inflammation Chronic
Skin	Inflammation Chronic
Skin: Tail, Epidermis	Hyperplasia
Spleen	Hematopoietic Cell Proliferation
	Pigmentation
Spleen: Lymphoid Follicle	Atrophy
Stomach, Forestomach	Inflammation
	Ulcer
Stomach, Forestomach: Epithelium	Hyperplasia
Stomach, Glandular	Erosion
Testes	Giant Cell
Testes: Germinal Epithelium	Atrophy
Thymus	Atrophy
	Cyst
	Necrosis Lymphoid
Thyroid Gland: Follicle	Degeneration
	Hypertrophy

FEMALE MICE

Organ

Adrenal Cortex

Bone

Clitoral Gland

Morphology

Accessory Adrenal Cortical Nodule

Hypertrophy Diffuse

Fibro-osseous Lesion

Inflammation Chronic

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF PENTABROMODIPHENYL OXIDE (TECHNICAL) (DE 71)

Heart	Cardiomyopathy
Kidney	Infiltration Cellular Mononuclear Cell
	Mineralization
	Nephropathy
	Dilatation
Kidney: Renal Tubule	Clear Cell Focus
Liver	Eosinophilic Focus
	Fatty Change
	Hematopoietic Cell Proliferation
	Hemorrhage
	Inflammation Chronic
	Necrosis Focal
Liver: Hepatocyte, Centrilobular	Hypertrophy
Liver: Kupffer Cell	Pigmentation
Lung	Hemorrhage
Lymph Node, Mandibular	Pigmentation
Lymph Node, Mesenteric	Ectasia
	Necrosis Lymphoid
	Pigmentation
Mammary Gland	Galactocele
	Hyperplasia
Nose	Inflammation Acute
Ovary	Cyst
Pancreas	Atrophy
	Inflammation Chronic
Pituitary Gland: Pars Distalis	Hyperplasia
Salivary Glands	Mineralization
Skin	Inflammation Chronic
	Ulcer
Spleen	Hematopoietic Cell Proliferation
	Pigmentation
Spleen: Lymphoid Follicle	Hyperplasia
Stomach, Forestomach	Erosion
	Inflammation
	Ulcer
Stomach, Forestomach: Epithelium	Hyperplasia

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT ($P \leq .05$) RESULTS IN THE ANALYSIS OF PENTABROMODIPHENYL OXIDE (TECHNICAL) (DE 71)

Thymus

Atrophy

Cyst

Hyperplasia Lymphoid

Thyroid Gland: Follicle

Degeneration

Hypertrophy

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex				
Accessory Adrenal Cortical Nodule				
LESION RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	7/49 (14%)	1/48 (2%)
POLY-3 RATE (b)	2/40.50	2/43.38	7/43.71	1/18.21
POLY-3 PERCENT (g)	4.9%	4.6%	16%	5.5%
TERMINAL (d)	0/29 (0%)	2/33 (6%)	5/31 (16%)	0/0 (0%)
FIRST INCIDENCE	598	729 (T)	581	543
STATISTICAL TESTS				
POLY 3	P=0.214	P=0.669N	P=0.097	P=0.684
POLY 1.5	P=0.486	P=0.676N	P=0.089	P=0.640N
POLY 6	P=0.044*	P=0.663N	P=0.108	P=0.508
COCH-ARM / FISHERS	P=0.383N	P=0.691N	P=0.075	P=0.515N
MAX-ISO-POLY-3	P=0.352	P=0.472N	P=0.056	P=0.475

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex Degeneration Fatty				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/49 (2%)	2/48 (4%)
POLY-3 RATE (b)	1/40.55	0/43.38	1/43.31	2/18.88
POLY-3 PERCENT (g)	2.5%	0%	2.3%	10.6%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	569	---	656	515
STATISTICAL TESTS				
POLY 3	P=0.093	P=0.487N	P=0.746N	P=0.269
POLY 1.5	P=0.126	P=0.490N	P=0.752N	P=0.364
POLY 6	P=0.158	P=0.483N	P=0.737N	P=0.167
COCH-ARM / FISHERS	P=0.207	P=0.500N	P=0.747	P=0.485
MAX-ISO-POLY-3	P=0.154	P=0.158N	P=0.481N	P=0.178

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex				
Hematopoietic Cell Proliferation				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.04	0/17.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex Hemorrhage				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.04	0/17.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/49 (2%)	0/48 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	1/43.04	0/17.62
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex				
Hypertrophy Diffuse				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	3/49 (6%)	20/48 (42%)
POLY-3 RATE (b)	1/40.45	0/43.38	3/43.18	20/30.02
POLY-3 PERCENT (g)	2.5%	0%	7%	66.6%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	606	---	708	451
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.486N	P=0.329	P<0.001**
POLY 1.5	P<0.001**	P=0.490N	P=0.319	P<0.001**
POLY 6	P<0.001**	P=0.482N	P=0.342	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500N	P=0.301	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.158N	P=0.179	P<0.001**

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex				
Hypertrophy Focal				
LESION RATES				
OVERALL (a)	10/50 (20%)	10/50 (20%)	5/49 (10%)	3/48 (6%)
POLY-3 RATE (b)	10/40.58	10/43.38	5/43.43	3/19.52
POLY-3 PERCENT (g)	24.6%	23.1%	11.5%	15.4%
TERMINAL (d)	8/29 (28%)	10/33 (30%)	4/31 (13%)	0/0 (0%)
FIRST INCIDENCE	626	729 (T)	618	477
STATISTICAL TESTS				
POLY 3	P=0.136N	P=0.534N	P=0.097N	P=0.330N
POLY 1.5	P=0.078N	P=0.550N	P=0.110N	P=0.143N
POLY 6	P=0.165N	P=0.518N	P=0.083N	P=0.536
COCH-ARM / FISHERS	P=0.021N*	P=0.598N	P=0.140N	P=0.042N*
MAX-ISO-POLY-3	P=0.224N	P=0.432N	P=0.063N	P=0.279N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex: Capsule Hyperplasia				
LESION RATES				
OVERALL (a)	42/50 (84%)	41/50 (82%)	47/49 (96%)	41/48 (85%)
POLY-3 RATE (b)	42/46.79	41/48.01	47/48.46	41/42.94
POLY-3 PERCENT (g)	89.8%	85.4%	97%	95.5%
TERMINAL (d)	26/29 (90%)	29/33 (88%)	31/31 (100%)	0/0 (0%)
FIRST INCIDENCE	491	428	431	451
STATISTICAL TESTS				
POLY 3	P=0.074	P=0.361N	P=0.132	P=0.233
POLY 1.5	P=0.138	P=0.363N	P=0.113	P=0.332
POLY 6	P=0.033*	P=0.385N	P=0.145	P=0.135
COCH-ARM / FISHERS	P=0.447	P=0.500N	P=0.049*	P=0.535
MAX-ISO-POLY-3	P=0.085	P=0.249N	P=0.062	P=0.123

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

**Bone Marrow: Myeloid Cell
Hyperplasia**

LESION RATES

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/40.94	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	4.9%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	592	---	---	---

STATISTICAL TESTS

POLY 3	P=0.277N	P=0.224N	P=0.221N	P=0.439N
POLY 1.5	P=0.297N	P=0.227N	P=0.226N	P=0.336N
POLY 6	P=0.303N	P=0.221N	P=0.216N	P=0.586N
COCH-ARM / FISHERS	P=0.289N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.303N	P=0.075N	P=0.075N	P=0.262N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Bone				
Fibro-osseous Lesion				
LESION RATES				
OVERALL (a)	2/49 (4%)	1/50 (2%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/40.71	1/43.38	0/43.98	0/17.74
POLY-3 PERCENT (g)	4.9%	2.3%	0%	0%
TERMINAL (d)	1/29 (3%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	494	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.196N	P=0.478N	P=0.220N	P=0.443N
POLY 1.5	P=0.205N	P=0.484N	P=0.225N	P=0.341N
POLY 6	P=0.202N	P=0.471N	P=0.213N	P=0.588N
COCH-ARM / FISHERS	P=0.187N	P=0.492N	P=0.242N	P=0.247N
MAX-ISO-POLY-3	P=0.322N	P=0.267N	P=0.074N	P=0.266N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Bone: Tail Callus				
LESION RATES				
OVERALL (a)	0/49 (0%)	2/50 (4%)	0/50 (0%)	1/49 (2%)
POLY-3 RATE (b)	0/40.02	2/43.38	0/43.98	1/18.33
POLY-3 PERCENT (g)	0%	4.6%	0%	5.5%
TERMINAL (d)	0/29 (0%)	2/33 (6%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	---	543
STATISTICAL TESTS				
POLY 3	P=0.560	P=0.255	(e)	P=0.362
POLY 1.5	P=0.576	P=0.250	(e)	P=0.423
POLY 6	P=0.663N	P=0.262	(e)	P=0.290
COCH-ARM / FISHERS	P=0.659	P=0.253	(e)	P=0.500
MAX-ISO-POLY-3	P=0.334	P=0.092	(e)	P=0.156

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Bone: Tail Developmental Malformation				
LESION RATES				
OVERALL (a)	1/49 (2%)	3/50 (6%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	1/40.02	3/43.38	0/43.98	0/17.74
POLY-3 PERCENT (g)	2.5%	6.9%	0%	0%
TERMINAL (d)	1/29 (3%)	3/33 (9%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.153N	P=0.334	P=0.481N	P=0.641N
POLY 1.5	P=0.155N	P=0.326	P=0.487N	P=0.579N
POLY 6	P=0.153N	P=0.344	P=0.473N	P=0.714N
COCH-ARM / FISHERS	P=0.133N	P=0.316	P=0.495N	P=0.500N
MAX-ISO-POLY-3	P=0.252N	P=0.182	P=0.157N	P=0.328N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Bone: Vertebra Callus				
LESION RATES				
OVERALL (a)	2/49 (4%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/40.91	0/43.38	0/43.98	0/17.74
POLY-3 PERCENT (g)	4.9%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	598	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.274N	P=0.224N	P=0.221N	P=0.444N
POLY 1.5	P=0.294N	P=0.227N	P=0.226N	P=0.342N
POLY 6	P=0.299N	P=0.221N	P=0.216N	P=0.589N
COCH-ARM / FISHERS	P=0.290N	P=0.242N	P=0.242N	P=0.247N
MAX-ISO-POLY-3	P=0.310N	P=0.074N	P=0.074N	P=0.267N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Brain Compression				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Brain Hemorrhage				
LESION RATES				
OVERALL (a)	6/50 (12%)	2/50 (4%)	2/50 (4%)	5/50 (10%)
POLY-3 RATE (b)	6/41.20	2/43.84	2/44.86	5/21.38
POLY-3 PERCENT (g)	14.6%	4.6%	4.5%	23.4%
TERMINAL (d)	2/29 (7%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	600	596	431	477
STATISTICAL TESTS				
POLY 3	P=0.193	P=0.112N	P=0.106N	P=0.316
POLY 1.5	P=0.251	P=0.118N	P=0.114N	P=0.519
POLY 6	P=0.273	P=0.108N	P=0.098N	P=0.112
COCH-ARM / FISHERS	P=0.415	P=0.134N	P=0.134N	P=0.500N
MAX-ISO-POLY-3	P=0.157	P=0.061N	P=0.059N	P=0.262

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Brain
Infiltration Cellular Mononuclear Cell

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	2/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/29 (0%)	2/33 (6%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	---	---

STATISTICAL TESTS

POLY 3	P=0.319N	P=0.255	(e)	(e)
POLY 1.5	P=0.330N	P=0.250	(e)	(e)
POLY 6	P=0.371N	P=0.262	(e)	(e)
COCH-ARM / FISHERS	P=0.326N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.510N	P=0.093	(e)	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Epididymis Inflammation Chronic				
LESION RATES				
OVERALL (a)	22/50 (44%)	28/50 (56%)	24/50 (48%)	7/50 (14%)
POLY-3 RATE (b)	22/43.25	28/45.54	24/45.39	7/22.26
POLY-3 PERCENT (g)	50.9%	61.5%	52.9%	31.4%
TERMINAL (d)	14/29 (48%)	22/33 (67%)	18/31 (58%)	0/0 (0%)
FIRST INCIDENCE	568	556	612	543
STATISTICAL TESTS				
POLY 3	P=0.057N	P=0.207	P=0.510	P=0.114N
POLY 1.5	P=0.003N**	P=0.201	P=0.490	P=0.013N*
POLY 6	P=0.398N	P=0.209	P=0.533	P=0.586
COCH-ARM / FISHERS	P<0.001N**	P=0.159	P=0.421	P<0.001N**
MAX-ISO-POLY-3	P=0.094N	P=0.156	P=0.424	P=0.122N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Esophagus				
Inflammation Acute				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/41.02	0/43.38	0/43.98	2/20.16
POLY-3 PERCENT (g)	2.4%	0%	0%	9.9%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	3	---	---	3
STATISTICAL TESTS				
POLY 3	P=0.119	P=0.489N	P=0.486N	P=0.282
POLY 1.5	P=0.128	P=0.493N	P=0.492N	P=0.382
POLY 6	P=0.309	P=0.484N	P=0.479N	P=0.173
COCH-ARM / FISHERS	P=0.173	P=0.500N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.104	P=0.158N	P=0.158N	P=0.185

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Esophagus				
Necrosis				
<hr/>				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/41.02	0/43.38	0/43.98	2/20.16
POLY-3 PERCENT (g)	2.4%	0%	0%	9.9%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	3	---	---	3
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.119	P=0.489N	P=0.486N	P=0.282
POLY 1.5	P=0.128	P=0.493N	P=0.492N	P=0.382
POLY 6	P=0.309	P=0.484N	P=0.479N	P=0.173
COCH-ARM / FISHERS	P=0.173	P=0.500N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.104	P=0.158N	P=0.158N	P=0.185

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Esophagus: Muscularis Degeneration

LESION RATES

OVERALL (a)	0/50 (0%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	2/43.94	2/44.48	0/18.16
POLY-3 PERCENT (g)	0%	4.6%	4.5%	0%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	---	557	581	---

STATISTICAL TESTS

POLY 3	P=0.620N	P=0.258	P=0.261	(e)
POLY 1.5	P=0.483N	P=0.252	P=0.253	(e)
POLY 6	P=0.491	P=0.267	P=0.273	(e)
COCH-ARM / FISHERS	P=0.344N	P=0.247	P=0.247	(e)
MAX-ISO-POLY-3	P=0.501	P=0.096	P=0.099	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Harderian Gland Hyperplasia				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/49 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/40.02	2/42.38	1/43.98	0/18.16
POLY-3 PERCENT (g)	2.5%	4.7%	2.3%	0%
TERMINAL (d)	1/29 (3%)	2/32 (6%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.348N	P=0.520	P=0.739N	P=0.638N
POLY 1.5	P=0.290N	P=0.512	P=0.746N	P=0.575N
POLY 6	P=0.485N	P=0.529	P=0.730N	P=0.713N
COCH-ARM / FISHERS	P=0.216N	P=0.492	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.510N	P=0.303	P=0.473N	P=0.324N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Heart				
Cardiomyopathy				
LESION RATES				
OVERALL (a)	8/50 (16%)	10/50 (20%)	7/50 (14%)	1/50 (2%)
POLY-3 RATE (b)	8/42.34	10/44.18	7/44.48	1/18.77
POLY-3 PERCENT (g)	18.9%	22.6%	15.7%	5.3%
TERMINAL (d)	3/29 (10%)	8/33 (24%)	5/31 (16%)	0/0 (0%)
FIRST INCIDENCE	494	603	612	530
STATISTICAL TESTS				
POLY 3	P=0.117N	P=0.435	P=0.458N	P=0.193N
POLY 1.5	P=0.039N*	P=0.429	P=0.468N	P=0.069N
POLY 6	P=0.277N	P=0.440	P=0.446N	P=0.500N
COCH-ARM / FISHERS	P=0.005N**	P=0.398	P=0.500N	P=0.015N*
MAX-ISO-POLY-3	P=0.193N	P=0.337	P=0.351N	P=0.175N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Heart Mineralization				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	5/50 (10%)	5/50 (10%)
POLY-3 RATE (b)	1/40.02	0/43.38	5/44.72	5/21.56
POLY-3 PERCENT (g)	2.5%	0%	11.2%	23.2%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	612	451
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.484N	P=0.128	P=0.020*
POLY 1.5	P=0.005**	P=0.489N	P=0.119	P=0.045*
POLY 6	P<0.001**	P=0.478N	P=0.143	P=0.006**
COCH-ARM / FISHERS	P=0.027*	P=0.500N	P=0.102	P=0.102
MAX-ISO-POLY-3	P=0.002**	P=0.158N	P=0.069	P=0.024*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Islets, Pancreatic Hyperplasia				
LESION RATES				
OVERALL (a)	32/50 (64%)	25/50 (50%)	21/50 (42%)	6/50 (12%)
POLY-3 RATE (b)	32/45.80	25/47.66	21/47.96	6/22.00
POLY-3 PERCENT (g)	69.9%	52.5%	43.8%	27.3%
TERMINAL (d)	19/29 (66%)	16/33 (49%)	10/31 (32%)	0/0 (0%)
FIRST INCIDENCE	491	428	431	451
STATISTICAL TESTS				
POLY 3	P=0.003N**	P=0.060N	P=0.007N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.067N	P=0.009N**	P<0.001N**
POLY 6	P=0.034N*	P=0.058N	P=0.007N**	P=0.178N
COCH-ARM / FISHERS	P<0.001N**	P=0.113N	P=0.022N*	P<0.001N**
MAX-ISO-POLY-3	P=0.005N**	P=0.040N*	P=0.005N**	P=0.003N**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney Infarct				
LESION RATES				
OVERALL (a)	3/50 (6%)	1/50 (2%)	5/49 (10%)	0/50 (0%)
POLY-3 RATE (b)	3/40.28	1/43.38	5/43.21	0/18.16
POLY-3 PERCENT (g)	7.5%	2.3%	11.6%	0%
TERMINAL (d)	2/29 (7%)	1/33 (3%)	4/31 (13%)	0/0 (0%)
FIRST INCIDENCE	660	729 (T)	684	---
STATISTICAL TESTS				
POLY 3	P=0.539	P=0.279N	P=0.395	P=0.315N
POLY 1.5	P=0.392N	P=0.286N	P=0.379	P=0.205N
POLY 6	P=0.231	P=0.271N	P=0.417	P=0.506N
COCH-ARM / FISHERS	P=0.173N	P=0.309N	P=0.346	P=0.121N
MAX-ISO-POLY-3	P=0.413N	P=0.144N	P=0.271	P=0.211N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney				
Infiltration Cellular Mononuclear Cell				
LESION RATES				
OVERALL (a)	35/50 (70%)	41/50 (82%)	39/49 (80%)	26/50 (52%)
POLY-3 RATE (b)	35/44.87	41/46.72	39/47.90	26/34.24
POLY-3 PERCENT (g)	78%	87.8%	81.4%	75.9%
TERMINAL (d)	24/29 (83%)	30/33 (91%)	25/31 (81%)	0/0 (0%)
FIRST INCIDENCE	491	540	453	442
STATISTICAL TESTS				
POLY 3	P=0.234N	P=0.145	P=0.438	P=0.524N
POLY 1.5	P=0.044N*	P=0.149	P=0.346	P=0.213N
POLY 6	P=0.452	P=0.156	P=0.577	P=0.252
COCH-ARM / FISHERS	P=0.002N**	P=0.121	P=0.193	P=0.050N*
MAX-ISO-POLY-3	P=0.373N	P=0.091	P=0.340	P=0.409N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney				
Metaplasia Osseous				
LESION RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/40.02	2/43.38	1/43.04	0/18.16
POLY-3 PERCENT (g)	5%	4.6%	2.3%	0%
TERMINAL (d)	2/29 (7%)	2/33 (6%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.254N	P=0.665N	P=0.475N	P=0.434N
POLY 1.5	P=0.208N	P=0.673N	P=0.485N	P=0.333N
POLY 6	P=0.351N	P=0.655N	P=0.461N	P=0.582N
COCH-ARM / FISHERS	P=0.142N	P=0.691N	P=0.508N	P=0.247N
MAX-ISO-POLY-3	P=0.413N	P=0.467N	P=0.267N	P=0.258N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney Mineralization				
LESION RATES				
OVERALL (a)	36/50 (72%)	32/50 (64%)	24/49 (49%)	6/50 (12%)
POLY-3 RATE (b)	36/45.54	32/47.52	24/45.03	6/21.82
POLY-3 PERCENT (g)	79.1%	67.4%	53.3%	27.5%
TERMINAL (d)	22/29 (76%)	24/33 (73%)	17/31 (55%)	0/0 (0%)
FIRST INCIDENCE	491	428	551	477
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.139N	P=0.006N**	P<0.001N**
POLY 1.5	P<0.001N**	P=0.157N	P=0.007N**	P<0.001N**
POLY 6	P=0.007N**	P=0.137N	P=0.006N**	P=0.051N
COCH-ARM / FISHERS	P<0.001N**	P=0.260N	P=0.016N*	P<0.001N**
MAX-ISO-POLY-3	P<0.001N**	P=0.097N	P=0.003N**	P<0.001N**

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney Nephropathy				
LESION RATES				
OVERALL (a)	38/50 (76%)	45/50 (90%)	37/49 (76%)	9/50 (18%)
POLY-3 RATE (b)	38/45.33	45/47.53	37/46.71	9/23.60
POLY-3 PERCENT (g)	83.8%	94.7%	79.2%	38.1%
TERMINAL (d)	26/29 (90%)	33/33 (100%)	25/31 (81%)	0/0 (0%)
FIRST INCIDENCE	298	556	453	501
STATISTICAL TESTS				
POLY 3	P<0.001N**	P=0.055	P=0.373N	P<0.001N**
POLY 1.5	P<0.001N**	P=0.060	P=0.436N	P<0.001N**
POLY 6	P<0.001N**	P=0.062	P=0.282N	P=0.026N*
COCH-ARM / FISHERS	P<0.001N**	P=0.054	P=0.570N	P<0.001N**
MAX-ISO-POLY-3	P<0.001N**	P=0.026*	P=0.275N	P<0.001N**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Interstitium Inflammation Chronic				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/40.02	1/43.38	1/43.04	0/18.16
POLY-3 PERCENT (g)	5%	2.3%	2.3%	0%
TERMINAL (d)	2/29 (7%)	1/33 (3%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.340N	P=0.472N	P=0.475N	P=0.434N
POLY 1.5	P=0.284N	P=0.480N	P=0.485N	P=0.333N
POLY 6	P=0.474N	P=0.462N	P=0.461N	P=0.582N
COCH-ARM / FISHERS	P=0.208N	P=0.500N	P=0.508N	P=0.247N
MAX-ISO-POLY-3	P=0.421N	P=0.265N	P=0.267N	P=0.258N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Papilla Inflammation Acute				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/40.47	2/44.72	0/43.04	0/18.16
POLY-3 PERCENT (g)	2.5%	4.5%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	600	428	---	---
STATISTICAL TESTS				
POLY 3	P=0.216N	P=0.535	P=0.488N	P=0.639N
POLY 1.5	P=0.218N	P=0.524	P=0.493N	P=0.576N
POLY 6	P=0.236N	P=0.546	P=0.481N	P=0.714N
COCH-ARM / FISHERS	P=0.198N	P=0.500	P=0.505N	P=0.500N
MAX-ISO-POLY-3	P=0.355N	P=0.318	P=0.160N	P=0.326N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Papilla Necrosis				
LESION RATES				
OVERALL (a)	4/50 (8%)	6/50 (12%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	4/40.91	6/45.40	2/43.46	0/18.16
POLY-3 PERCENT (g)	9.8%	13.2%	4.6%	0%
TERMINAL (d)	2/29 (7%)	2/33 (6%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	600	428	627	---
STATISTICAL TESTS				
POLY 3	P=0.077N	P=0.436	P=0.309N	P=0.239N
POLY 1.5	P=0.045N*	P=0.416	P=0.321N	P=0.131N
POLY 6	P=0.118N	P=0.460	P=0.294N	P=0.454N
COCH-ARM / FISHERS	P=0.017N*	P=0.370	P=0.349N	P=0.059N
MAX-ISO-POLY-3	P=0.126N	P=0.319	P=0.187N	P=0.177N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

**Kidney: Renal Tubule
Accumulation, Hyaline Droplet**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.04	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Renal Tubule Cyst				
LESION RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	1/49 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/40.06	2/43.38	1/43.31	0/18.16
POLY-3 PERCENT (g)	5%	4.6%	2.3%	0%
TERMINAL (d)	1/29 (3%)	2/33 (6%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	721	729 (T)	656	---
STATISTICAL TESTS				
POLY 3	P=0.253N	P=0.665N	P=0.473N	P=0.434N
POLY 1.5	P=0.207N	P=0.673N	P=0.484N	P=0.333N
POLY 6	P=0.347N	P=0.656N	P=0.457N	P=0.582N
COCH-ARM / FISHERS	P=0.142N	P=0.691N	P=0.508N	P=0.247N
MAX-ISO-POLY-3	P=0.412N	P=0.468N	P=0.266N	P=0.258N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Renal Tubule Degeneration				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	2/49 (4%)	0/50 (0%)
POLY-3 RATE (b)	3/41.37	0/43.38	2/43.49	0/18.16
POLY-3 PERCENT (g)	7.3%	0%	4.6%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	589	---	618	---
STATISTICAL TESTS				
POLY 3	P=0.450N	P=0.110N	P=0.477N	P=0.323N
POLY 1.5	P=0.335N	P=0.112N	P=0.486N	P=0.209N
POLY 6	P=0.673N	P=0.109N	P=0.466N	P=0.513N
COCH-ARM / FISHERS	P=0.212N	P=0.121N	P=0.510N	P=0.121N
MAX-ISO-POLY-3	P=0.326N	P=0.038N*	P=0.308N	P=0.218N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Renal Tubule Dilatation				
LESION RATES				
OVERALL (a)	14/50 (28%)	14/50 (28%)	15/49 (31%)	9/50 (18%)
POLY-3 RATE (b)	14/41.05	14/44.93	15/43.29	9/23.64
POLY-3 PERCENT (g)	34.1%	31.2%	34.7%	38.1%
TERMINAL (d)	11/29 (38%)	11/33 (33%)	13/31 (42%)	0/0 (0%)
FIRST INCIDENCE	568	540	684	442
STATISTICAL TESTS				
POLY 3	P=0.369	P=0.476N	P=0.571	P=0.480
POLY 1.5	P=0.438N	P=0.510N	P=0.541	P=0.437N
POLY 6	P=0.144	P=0.437N	P=0.579N	P=0.132
COCH-ARM / FISHERS	P=0.113N	P=0.588N	P=0.474	P=0.171N
MAX-ISO-POLY-3	P=0.581	P=0.388N	P=0.478	P=0.397

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Renal Tubule Pigmentation				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	3/49 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/40.02	0/43.38	3/43.31	0/18.16
POLY-3 PERCENT (g)	2.5%	0%	6.9%	0%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	656	---
STATISTICAL TESTS				
POLY 3	P=0.393	P=0.484N	P=0.334	P=0.638N
POLY 1.5	P=0.630	P=0.489N	P=0.322	P=0.575N
POLY 6	P=0.159	P=0.478N	P=0.351	P=0.713N
COCH-ARM / FISHERS	P=0.460N	P=0.500N	P=0.301	P=0.500N
MAX-ISO-POLY-3	P=0.505	P=0.158N	P=0.184	P=0.324N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Basophilic Focus				
LESION RATES				
OVERALL (a)	6/50 (12%)	3/50 (6%)	1/50 (2%)	5/50 (10%)
POLY-3 RATE (b)	6/40.28	3/43.38	1/44.04	5/21.10
POLY-3 PERCENT (g)	14.9%	6.9%	2.3%	23.7%
TERMINAL (d)	5/29 (17%)	3/33 (9%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	660	729 (T)	715	537
STATISTICAL TESTS				
POLY 3	P=0.289	P=0.205N	P=0.042N*	P=0.321
POLY 1.5	P=0.333	P=0.215N	P=0.046N*	P=0.522
POLY 6	P=0.437	P=0.194N	P=0.037N*	P=0.115
COCH-ARM / FISHERS	P=0.486	P=0.243N	P=0.056N	P=0.500N
MAX-ISO-POLY-3	P=0.157	P=0.128N	P=0.021N*	P=0.265

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Clear Cell Focus				
LESION RATES				
OVERALL (a)	10/50 (20%)	13/50 (26%)	20/50 (40%)	7/50 (14%)
POLY-3 RATE (b)	10/41.69	13/44.86	20/45.10	7/22.28
POLY-3 PERCENT (g)	24%	29%	44.3%	31.4%
TERMINAL (d)	6/29 (21%)	10/33 (30%)	17/31 (55%)	0/0 (0%)
FIRST INCIDENCE	521	428	551	535
STATISTICAL TESTS				
POLY 3	P=0.181	P=0.389	P=0.035*	P=0.373
POLY 1.5	P=0.549	P=0.371	P=0.031*	P=0.586N
POLY 6	P=0.020*	P=0.404	P=0.040*	P=0.107
COCH-ARM / FISHERS	P=0.121N	P=0.318	P=0.024*	P=0.298N
MAX-ISO-POLY-3	P=0.298	P=0.305	P=0.024*	P=0.315

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Eosinophilic Focus				
LESION RATES				
OVERALL (a)	15/50 (30%)	22/50 (44%)	10/50 (20%)	11/50 (22%)
POLY-3 RATE (b)	15/42.77	22/45.69	10/45.40	11/25.07
POLY-3 PERCENT (g)	35.1%	48.2%	22%	43.9%
TERMINAL (d)	10/29 (35%)	17/33 (52%)	7/31 (23%)	0/0 (0%)
FIRST INCIDENCE	491	428	453	442
STATISTICAL TESTS				
POLY 3	P=0.379N	P=0.147	P=0.128N	P=0.325
POLY 1.5	P=0.210N	P=0.138	P=0.141N	P=0.574N
POLY 6	P=0.525N	P=0.158	P=0.114N	P=0.063
COCH-ARM / FISHERS	P=0.049N*	P=0.107	P=0.178N	P=0.247N
MAX-ISO-POLY-3	P=0.379N	P=0.109	P=0.091N	P=0.282

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Fatty Change				
LESION RATES				
OVERALL (a)	17/50 (34%)	25/50 (50%)	17/50 (34%)	5/50 (10%)
POLY-3 RATE (b)	17/44.92	25/46.83	17/47.82	5/21.09
POLY-3 PERCENT (g)	37.9%	53.4%	35.6%	23.7%
TERMINAL (d)	8/29 (28%)	16/33 (49%)	9/31 (29%)	0/0 (0%)
FIRST INCIDENCE	298	428	431	543
STATISTICAL TESTS				
POLY 3	P=0.055N	P=0.095	P=0.494N	P=0.216N
POLY 1.5	P=0.006N**	P=0.092	P=0.522N	P=0.044N*
POLY 6	P=0.210N	P=0.102	P=0.459N	P=0.512
COCH-ARM / FISHERS	P<0.001N**	P=0.078	P=0.583N	P=0.004N**
MAX-ISO-POLY-3	P=0.090N	P=0.068	P=0.410N	P=0.208N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Hematopoietic Cell Proliferation				
LESION RATES				
OVERALL (a)	10/50 (20%)	5/50 (10%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	10/41.85	5/43.38	1/43.98	3/20.09
POLY-3 PERCENT (g)	23.9%	11.5%	2.3%	14.9%
TERMINAL (d)	7/29 (24%)	5/33 (15%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	298	729 (T)	729 (T)	451
STATISTICAL TESTS				
POLY 3	P=0.138N	P=0.110N	P=0.003N**	P=0.333N
POLY 1.5	P=0.125N	P=0.115N	P=0.003N**	P=0.138N
POLY 6	P=0.081N	P=0.104N	P=0.002N**	P=0.525
COCH-ARM / FISHERS	P=0.066N	P=0.131N	P=0.004N**	P=0.036N*
MAX-ISO-POLY-3	P=0.169N	P=0.068N	P<0.001N**	P=0.283N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver Hemorrhage				
LESION RATES				
OVERALL (a)	3/50 (6%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	3/41.00	1/43.38	1/44.39	2/19.36
POLY-3 PERCENT (g)	7.3%	2.3%	2.3%	10.3%
TERMINAL (d)	1/29 (3%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	568	729 (T)	612	527
STATISTICAL TESTS				
POLY 3	P=0.433	P=0.285N	P=0.277N	P=0.536
POLY 1.5	P=0.490	P=0.289N	P=0.286N	P=0.665N
POLY 6	P=0.571	P=0.280N	P=0.266N	P=0.326
COCH-ARM / FISHERS	P=0.630	P=0.309N	P=0.309N	P=0.500N
MAX-ISO-POLY-3	P=0.402	P=0.146N	P=0.144N	P=0.391

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	13/50 (26%)	19/50 (38%)	22/50 (44%)	12/50 (24%)
POLY-3 RATE (b)	13/41.57	19/44.94	22/44.92	12/25.28
POLY-3 PERCENT (g)	31.3%	42.3%	49%	47.5%
TERMINAL (d)	9/29 (31%)	16/33 (49%)	18/31 (58%)	0/0 (0%)
FIRST INCIDENCE	569	557	612	528
STATISTICAL TESTS				
POLY 3	P=0.158	P=0.198	P=0.067	P=0.144
POLY 1.5	P=0.463	P=0.182	P=0.060	P=0.365
POLY 6	P=0.023*	P=0.215	P=0.079	P=0.019*
COCH-ARM / FISHERS	P=0.183N	P=0.142	P=0.046*	P=0.500N
MAX-ISO-POLY-3	P=0.249	P=0.149	P=0.048*	P=0.137

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Mixed Cell Focus				
LESION RATES				
OVERALL (a)	2/50 (4%)	5/50 (10%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/40.02	5/44.27	0/43.98	1/18.74
POLY-3 PERCENT (g)	5%	11.3%	0%	5.3%
TERMINAL (d)	2/29 (7%)	3/33 (9%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	596	---	543
STATISTICAL TESTS				
POLY 3	P=0.187N	P=0.258	P=0.216N	P=0.694
POLY 1.5	P=0.191N	P=0.245	P=0.223N	P=0.627N
POLY 6	P=0.129N	P=0.277	P=0.208N	P=0.515
COCH-ARM / FISHERS	P=0.149N	P=0.218	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.308N	P=0.160	P=0.075N	P=0.484

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Necrosis Focal				
LESION RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	16/50 (32%)	2/50 (4%)
POLY-3 RATE (b)	2/40.47	2/43.54	16/44.51	2/19.36
POLY-3 PERCENT (g)	4.9%	4.6%	36%	10.3%
TERMINAL (d)	1/29 (3%)	1/33 (3%)	13/31 (42%)	0/0 (0%)
FIRST INCIDENCE	598	689	627	530
STATISTICAL TESTS				
POLY 3	P=0.011*	P=0.668N	P<0.001**	P=0.420
POLY 1.5	P=0.172	P=0.675N	P<0.001**	P=0.553
POLY 6	P<0.001**	P=0.659N	P<0.001**	P=0.255
COCH-ARM / FISHERS	P=0.477N	P=0.691N	P<0.001**	P=0.691N
MAX-ISO-POLY-3	P=0.018*	P=0.470N	P<0.001**	P=0.294

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Liver				
Tension Lipidosis				
<hr/>				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	2.5%	0%	0%	0%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Liver: Centrilobular
Necrosis

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver: Hepatocyte, Centrilobular Hypertrophy				
LESION RATES				
OVERALL (a)	0/50 (0%)	28/50 (56%)	46/50 (92%)	48/50 (96%)
POLY-3 RATE (b)	0/40.02	28/45.29	46/49.86	48/48.00
POLY-3 PERCENT (g)	0%	61.8%	92.3%	100%
TERMINAL (d)	0/29 (0%)	21/33 (64%)	29/31 (94%)	0/0 (0%)
FIRST INCIDENCE	---	591	431	442
STATISTICAL TESTS				
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver: Kupffer Cell Pigmentation				
LESION RATES				
OVERALL (a)	5/50 (10%)	15/50 (30%)	33/50 (66%)	25/50 (50%)
POLY-3 RATE (b)	5/40.92	15/44.77	33/46.02	25/33.27
POLY-3 PERCENT (g)	12.2%	33.5%	71.7%	75.2%
TERMINAL (d)	3/29 (10%)	10/33 (30%)	22/31 (71%)	0/0 (0%)
FIRST INCIDENCE	568	614	581	451
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.017*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.015*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.020*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.011*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.011*	P<0.001**	P<0.001**

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung Congestion				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/40.02	0/43.38	0/43.98	2/19.70
POLY-3 PERCENT (g)	2.5%	0%	0%	10.2%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	442
STATISTICAL TESTS				
POLY 3	P=0.121	P=0.484N	P=0.481N	P=0.283
POLY 1.5	P=0.126	P=0.489N	P=0.487N	P=0.380
POLY 6	P=0.312	P=0.478N	P=0.473N	P=0.175
COCH-ARM / FISHERS	P=0.173	P=0.500N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.103	P=0.158N	P=0.158N	P=0.185

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Lung Hemorrhage				
<hr/>				
LESION RATES				
OVERALL (a)	10/50 (20%)	6/50 (12%)	6/50 (12%)	3/50 (6%)
POLY-3 RATE (b)	10/43.13	6/44.95	6/46.80	3/20.09
POLY-3 PERCENT (g)	23.2%	13.4%	12.8%	14.9%
TERMINAL (d)	5/29 (17%)	2/33 (6%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	3	556	453	451
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.318N	P=0.178N	P=0.156N	P=0.353N
POLY 1.5	P=0.195N	P=0.190N	P=0.177N	P=0.150N
POLY 6	P=0.406N	P=0.162N	P=0.133N	P=0.507
COCH-ARM / FISHERS	P=0.057N	P=0.207N	P=0.207N	P=0.036N*
MAX-ISO-POLY-3	P=0.438N	P=0.119N	P=0.107N	P=0.299N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung				
Infiltration Cellular Histiocyte				
LESION RATES				
OVERALL (a)	8/50 (16%)	11/50 (22%)	5/50 (10%)	1/50 (2%)
POLY-3 RATE (b)	8/40.55	11/43.38	5/44.57	1/18.92
POLY-3 PERCENT (g)	19.7%	25.4%	11.2%	5.3%
TERMINAL (d)	7/29 (24%)	11/33 (33%)	3/31 (10%)	0/0 (0%)
FIRST INCIDENCE	568	729 (T)	612	451
STATISTICAL TESTS				
POLY 3	P=0.043N*	P=0.361	P=0.215N	P=0.172N
POLY 1.5	P=0.017N*	P=0.347	P=0.235N	P=0.062N
POLY 6	P=0.071N	P=0.378	P=0.190N	P=0.473N
COCH-ARM / FISHERS	P=0.003N**	P=0.306	P=0.277N	P=0.015N*
MAX-ISO-POLY-3	P=0.071N	P=0.275	P=0.148N	P=0.156N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung Inflammation Acute				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/41.96	1/43.38	0/43.98	1/19.16
POLY-3 PERCENT (g)	4.8%	2.3%	0%	5.2%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	3	729 (T)	---	3
STATISTICAL TESTS				
POLY 3	P=0.534N	P=0.488N	P=0.227N	P=0.687
POLY 1.5	P=0.561N	P=0.494N	P=0.232N	P=0.632N
POLY 6	P=0.456N	P=0.481N	P=0.219N	P=0.509
COCH-ARM / FISHERS	P=0.525N	P=0.500N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.528N	P=0.273N	P=0.076N	P=0.478

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung				
Metaplasia Osseous				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	1/18.74
POLY-3 PERCENT (g)	0%	0%	0%	5.3%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	543
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung Mineralization				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	1/40.02	2/43.84	3/44.12	2/19.33
POLY-3 PERCENT (g)	2.5%	4.6%	6.8%	10.4%
TERMINAL (d)	1/29 (3%)	1/33 (3%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	596	708	543
STATISTICAL TESTS				
POLY 3	P=0.192	P=0.532	P=0.341	P=0.278
POLY 1.5	P=0.313	P=0.522	P=0.329	P=0.376
POLY 6	P=0.157	P=0.544	P=0.357	P=0.172
COCH-ARM / FISHERS	P=0.518	P=0.500	P=0.309	P=0.500
MAX-ISO-POLY-3	P=0.316	P=0.315	P=0.190	P=0.183

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung Thrombosis				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	3/40.71	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	7.4%	0%	0%	0%
TERMINAL (d)	2/29 (7%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	494	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.179N	P=0.107N	P=0.105N	P=0.318N
POLY 1.5	P=0.191N	P=0.110N	P=0.109N	P=0.207N
POLY 6	P=0.178N	P=0.103N	P=0.099N	P=0.508N
COCH-ARM / FISHERS	P=0.175N	P=0.121N	P=0.121N	P=0.121N
MAX-ISO-POLY-3	P=0.217N	P=0.037N*	P=0.037N*	P=0.214N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung: Alveolar Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	2/50 (4%)	6/50 (12%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/40.02	6/44.41	1/44.74	0/18.16
POLY-3 PERCENT (g)	5%	13.5%	2.2%	0%
TERMINAL (d)	2/29 (7%)	4/33 (12%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	540	453	---
STATISTICAL TESTS				
POLY 3	P=0.077N	P=0.168	P=0.461N	P=0.434N
POLY 1.5	P=0.058N	P=0.157	P=0.474N	P=0.333N
POLY 6	P=0.089N	P=0.183	P=0.445N	P=0.582N
COCH-ARM / FISHERS	P=0.033N*	P=0.134	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.126N	P=0.102	P=0.259N	P=0.258N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node Ectasia				
LESION RATES				
OVERALL (a)	0/5 (0%)	0/4 (0%)	0/4 (0%)	0/1 (0%)
POLY-3 RATE (b)	0/5.00	0/3.29	0/3.21	0/0.24
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/5 (0%)	0/2 (0%)	0/3 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node Hemorrhage				
LESION RATES				
OVERALL (a)	0/5 (0%)	0/4 (0%)	0/4 (0%)	0/1 (0%)
POLY-3 RATE (b)	0/5.00	0/3.29	0/3.21	0/0.24
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/5 (0%)	0/2 (0%)	0/3 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node				
Hyperplasia Lymphoid				
LESION RATES				
OVERALL (a)	1/5 (20%)	0/4 (0%)	0/4 (0%)	0/1 (0%)
POLY-3 RATE (b)	1/5.00	0/3.29	0/3.21	0/0.24
POLY-3 PERCENT (g)	20%	0%	0%	0%
TERMINAL (d)	1/5 (20%)	0/2 (0%)	0/3 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node Pigmentation				
LESION RATES				
OVERALL (a)	2/5 (40%)	0/4 (0%)	2/4 (50%)	0/1 (0%)
POLY-3 RATE (b)	2/5.00	0/3.29	2/3.21	0/0.24
POLY-3 PERCENT (g)	40%	0%	62.4%	0%
TERMINAL (d)	2/5 (40%)	0/2 (0%)	2/3 (67%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.394	P=0.319N	P=0.532	P=0.782N
POLY 1.5	P=0.523	P=0.294N	P=0.567	P=0.736N
POLY 6	P=0.343	P=0.356N	P=0.507	P=0.811N
COCH-ARM / FISHERS	P=0.740N	P=0.278N	P=0.643	P=0.667N
MAX-ISO-POLY-3	P=0.615N	P=0.132N	P=0.314	P=0.450N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mandibular Hemorrhage				
LESION RATES				
OVERALL (a)	2/50 (4%)	3/49 (6%)	0/49 (0%)	0/46 (0%)
POLY-3 RATE (b)	2/40.65	3/43.22	0/43.74	0/16.62
POLY-3 PERCENT (g)	4.9%	6.9%	0%	0%
TERMINAL (d)	0/29 (0%)	1/32 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	600	596	---	---
STATISTICAL TESTS				
POLY 3	P=0.109N	P=0.528	P=0.221N	P=0.457N
POLY 1.5	P=0.111N	P=0.517	P=0.227N	P=0.357N
POLY 6	P=0.099N	P=0.540	P=0.214N	P=0.597N
COCH-ARM / FISHERS	P=0.092N	P=0.490	P=0.253N	P=0.269N
MAX-ISO-POLY-3	P=0.179N	P=0.353	P=0.077N	P=0.275N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mandibular Hyperplasia Lymphoid				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/49 (2%)	0/49 (0%)	0/46 (0%)
POLY-3 RATE (b)	0/40.02	1/42.38	0/43.74	0/16.62
POLY-3 PERCENT (g)	0%	2.4%	0%	0%
TERMINAL (d)	0/29 (0%)	1/32 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mandibular Pigmentation				
LESION RATES				
OVERALL (a)	45/50 (90%)	48/49 (98%)	46/49 (94%)	44/46 (96%)
POLY-3 RATE (b)	45/46.69	48/49.00	46/49.00	44/44.40
POLY-3 PERCENT (g)	96.4%	98%	93.9%	99.1%
TERMINAL (d)	28/29 (97%)	31/32 (97%)	28/31 (90%)	0/0 (0%)
FIRST INCIDENCE	521	428	431	3
STATISTICAL TESTS				
POLY 3	P=0.386	P=0.567	P=0.460N	P=0.420
POLY 1.5	P=0.371	P=0.396	P=0.586N	P=0.325
POLY 6	P=0.378	P=0.699	P=0.365N	P=0.498
COCH-ARM / FISHERS	P=0.424	P=0.107	P=0.369	P=0.254
MAX-ISO-POLY-3	P=0.323	P=0.311	P=0.282N	P=0.144

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Atrophy				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/47 (0%)	0/46 (0%)	3/47 (6%)
POLY-3 RATE (b)	0/39.02	0/40.38	0/40.12	3/18.99
POLY-3 PERCENT (g)	0%	0%	0%	15.8%
TERMINAL (d)	0/28 (0%)	0/30 (0%)	0/29 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	543
STATISTICAL TESTS				
POLY 3	P=0.004**	(e)	(e)	P=0.039*
POLY 1.5	P=0.004**	(e)	(e)	P=0.064
POLY 6	P=0.027*	(e)	(e)	P=0.021*
COCH-ARM / FISHERS	P=0.008**	(e)	(e)	P=0.113
MAX-ISO-POLY-3	P=0.007**	(e)	(e)	P=0.032*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Congestion				
LESION RATES				
OVERALL (a)	1/49 (2%)	0/47 (0%)	3/46 (7%)	0/47 (0%)
POLY-3 RATE (b)	1/39.02	0/40.38	3/40.52	0/17.23
POLY-3 PERCENT (g)	2.6%	0%	7.4%	0%
TERMINAL (d)	1/28 (4%)	0/30 (0%)	2/29 (7%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	618	---
STATISTICAL TESTS				
POLY 3	P=0.393	P=0.493N	P=0.318	P=0.642N
POLY 1.5	P=0.628	P=0.497N	P=0.306	P=0.582N
POLY 6	P=0.158	P=0.488N	P=0.336	P=0.715N
COCH-ARM / FISHERS	P=0.467N	P=0.510N	P=0.285	P=0.510N
MAX-ISO-POLY-3	P=0.499	P=0.161N	P=0.171	P=0.327N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Ectasia				
LESION RATES				
OVERALL (a)	1/49 (2%)	1/47 (2%)	1/46 (2%)	2/47 (4%)
POLY-3 RATE (b)	1/39.55	1/40.98	1/40.88	2/18.72
POLY-3 PERCENT (g)	2.5%	2.4%	2.5%	10.7%
TERMINAL (d)	0/28 (0%)	0/30 (0%)	0/29 (0%)	0/0 (0%)
FIRST INCIDENCE	569	540	453	451
STATISTICAL TESTS				
POLY 3	P=0.189	P=0.753N	P=0.753N	P=0.273
POLY 1.5	P=0.240	P=0.757N	P=0.760N	P=0.366
POLY 6	P=0.273	P=0.748N	P=0.745N	P=0.169
COCH-ARM / FISHERS	P=0.354	P=0.742	P=0.737	P=0.484
MAX-ISO-POLY-3	P=0.265	P=0.489N	P=0.490N	P=0.179

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Hemorrhage				
LESION RATES				
OVERALL (a)	3/49 (6%)	7/47 (15%)	7/46 (15%)	8/47 (17%)
POLY-3 RATE (b)	3/39.91	7/41.93	7/40.76	8/22.21
POLY-3 PERCENT (g)	7.5%	16.7%	17.2%	36%
TERMINAL (d)	1/28 (4%)	3/30 (10%)	5/29 (17%)	0/0 (0%)
FIRST INCIDENCE	569	540	627	492
STATISTICAL TESTS				
POLY 3	P=0.018*	P=0.176	P=0.163	P=0.008**
POLY 1.5	P=0.052	P=0.165	P=0.153	P=0.026*
POLY 6	P=0.007**	P=0.189	P=0.178	P<0.001**
COCH-ARM / FISHERS	P=0.178	P=0.142	P=0.134	P=0.087
MAX-ISO-POLY-3	P=0.030*	P=0.109	P=0.099	P=0.012*

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Lymph Node, Mesenteric
Necrosis Lymphoid

LESION RATES

OVERALL (a)	0/49 (0%)	1/47 (2%)	0/46 (0%)	0/47 (0%)
POLY-3 RATE (b)	0/39.02	1/40.82	0/40.12	0/17.23
POLY-3 PERCENT (g)	0%	2.5%	0%	0%
TERMINAL (d)	0/28 (0%)	0/30 (0%)	0/29 (0%)	0/0 (0%)
FIRST INCIDENCE	---	603	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Lymph Node, Mesenteric Pigmentation

LESION RATES

OVERALL (a)	1/49 (2%)	0/47 (0%)	2/46 (4%)	4/47 (9%)
POLY-3 RATE (b)	1/39.47	0/40.38	2/40.60	4/19.58
POLY-3 PERCENT (g)	2.5%	0%	4.9%	20.4%
TERMINAL (d)	0/28 (0%)	0/30 (0%)	0/29 (0%)	0/0 (0%)
FIRST INCIDENCE	600	---	618	543

STATISTICAL TESTS

POLY 3	P=0.005**	P=0.495N	P=0.510	P=0.046*
POLY 1.5	P=0.011*	P=0.499N	P=0.499	P=0.086
POLY 6	P=0.009**	P=0.492N	P=0.524	P=0.018*
COCH-ARM / FISHERS	P=0.031*	P=0.510N	P=0.476	P=0.168
MAX-ISO-POLY-3	P=0.009**	P=0.161N	P=0.294	P=0.044*

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Mammary Gland				
Galactocele				
LESION RATES				
OVERALL (a)	0/2 (0%)	0/2 (0%)	0/1 (0%)	0/4 (0%)
POLY-3 RATE (b)	0/1.28	0/2.00	0/0.24	0/1.61
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/2 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Mammary Gland Hyperplasia				
LESION RATES				
OVERALL (a)	0/2 (0%)	0/2 (0%)	0/1 (0%)	0/4 (0%)
POLY-3 RATE (b)	0/1.28	0/2.00	0/0.24	0/1.61
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/2 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Mammary Gland Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/2 (0%)	0/2 (0%)	0/1 (0%)	0/4 (0%)
POLY-3 RATE (b)	0/1.28	0/2.00	0/0.24	0/1.61
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/2 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Mesentery: Artery Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/12 (0%)	0/3 (0%)	2/9 (22%)	2/5 (40%)
POLY-3 RATE (b)	0/9.62	0/2.20	2/7.27	2/3.05
POLY-3 PERCENT (g)	0%	0%	27.5%	65.7%
TERMINAL (d)	0/7 (0%)	0/2 (0%)	2/5 (40%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	543
STATISTICAL TESTS				
POLY 3	P=0.012*	(e)	P=0.157	P=0.018*
POLY 1.5	P=0.019*	(e)	P=0.157	P=0.026*
POLY 6	P=0.007**	(e)	P=0.157	P=0.011*
COCH-ARM / FISHERS	P=0.039*	(e)	P=0.171	P=0.074
MAX-ISO-POLY-3	P=0.020*	(e)	P=0.046*	P=0.007**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Mesentery: Fat Necrosis				
LESION RATES				
OVERALL (a)	8/12 (67%)	3/3 (100%)	6/9 (67%)	2/5 (40%)
POLY-3 RATE (b)	8/10.76	3/3.00	6/7.94	2/3.22
POLY-3 PERCENT (g)	74.4%	100%	75.6%	62.1%
TERMINAL (d)	6/7 (86%)	2/2 (100%)	4/5 (80%)	0/0 (0%)
FIRST INCIDENCE	491	428	618	451
STATISTICAL TESTS				
POLY 3	P=0.411N	P=0.426	P=0.691	P=0.609N
POLY 1.5	P=0.289N	P=0.377	P=0.671	P=0.464N
POLY 6	P=0.577N	P=0.527	P=0.730N	P=0.806
COCH-ARM / FISHERS	P=0.173N	P=0.363	P=0.676N	P=0.314N
MAX-ISO-POLY-3	P=0.492N	P=0.185	P=0.475	P=0.367N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Nose				
Foreign Body				
LESION RATES				
OVERALL (a)	4/50 (8%)	7/48 (15%)	7/50 (14%)	5/50 (10%)
POLY-3 RATE (b)	4/40.02	7/42.37	7/44.55	5/21.14
POLY-3 PERCENT (g)	10%	16.5%	15.7%	23.7%
TERMINAL (d)	4/29 (14%)	6/32 (19%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	618	684	528
STATISTICAL TESTS				
POLY 3	P=0.204	P=0.292	P=0.325	P=0.164
POLY 1.5	P=0.372	P=0.275	P=0.302	P=0.301
POLY 6	P=0.133	P=0.315	P=0.359	P=0.054
COCH-ARM / FISHERS	P=0.487N	P=0.239	P=0.262	P=0.500
MAX-ISO-POLY-3	P=0.291	P=0.201	P=0.230	P=0.144

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Nose				
Fungus				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/48 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/40.47	0/41.98	2/43.98	0/18.16
POLY-3 PERCENT (g)	2.5%	0%	4.6%	0%
TERMINAL (d)	0/29 (0%)	0/32 (0%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	598	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.528	P=0.493N	P=0.529	P=0.639N
POLY 1.5	P=0.616N	P=0.497N	P=0.520	P=0.576N
POLY 6	P=0.349	P=0.488N	P=0.540	P=0.714N
COCH-ARM / FISHERS	P=0.467N	P=0.510N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.563N	P=0.161N	P=0.312	P=0.326N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Nose				
Inflammation Acute				
LESION RATES				
OVERALL (a)	9/50 (18%)	12/48 (25%)	19/50 (38%)	6/50 (12%)
POLY-3 RATE (b)	9/41.37	12/42.34	19/44.80	6/21.87
POLY-3 PERCENT (g)	21.8%	28.3%	42.4%	27.4%
TERMINAL (d)	6/29 (21%)	11/32 (34%)	13/31 (42%)	0/0 (0%)
FIRST INCIDENCE	589	626	656	451
STATISTICAL TESTS				
POLY 3	P=0.230	P=0.328	P=0.031*	P=0.428
POLY 1.5	P=0.493N	P=0.316	P=0.028*	P=0.555N
POLY 6	P=0.029*	P=0.340	P=0.038*	P=0.144
COCH-ARM / FISHERS	P=0.104N	P=0.275	P=0.022*	P=0.288N
MAX-ISO-POLY-3	P=0.309	P=0.247	P=0.022*	P=0.352

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Nose
Mineralization

LESION RATES

OVERALL (a)	2/50 (4%)	2/48 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	2/40.02	2/41.98	2/44.39	0/18.16
POLY-3 PERCENT (g)	5%	4.8%	4.5%	0%
TERMINAL (d)	2/29 (7%)	2/32 (6%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	612	---

STATISTICAL TESTS

POLY 3	P=0.354N	P=0.677N	P=0.656N	P=0.434N
POLY 1.5	P=0.255N	P=0.686N	P=0.669N	P=0.333N
POLY 6	P=0.547N	P=0.666N	P=0.639N	P=0.582N
COCH-ARM / FISHERS	P=0.151N	P=0.676	P=0.691N	P=0.247N
MAX-ISO-POLY-3	P=0.479N	P=0.480N	P=0.459N	P=0.258N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas				
Atrophy				
<hr/>				
LESION RATES				
OVERALL (a)	10/50 (20%)	14/50 (28%)	7/50 (14%)	0/50 (0%)
POLY-3 RATE (b)	10/40.50	14/44.96	7/44.45	0/18.16
POLY-3 PERCENT (g)	24.7%	31.1%	15.8%	0%
TERMINAL (d)	9/29 (31%)	10/33 (30%)	5/31 (16%)	0/0 (0%)
FIRST INCIDENCE	589	556	612	---
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.011N*	P=0.336	P=0.224N	P=0.039N*
POLY 1.5	P=0.002N**	P=0.304	P=0.248N	P=0.007N**
POLY 6	P=0.037N*	P=0.380	P=0.194N	P=0.248N
COCH-ARM / FISHERS	P<0.001N**	P=0.241	P=0.298N	P<0.001N**
MAX-ISO-POLY-3	P=0.018N*	P=0.264	P=0.162N	P=0.052N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas				
Cyst				
<hr/>				
LESION RATES				
OVERALL (a)	1/50 (2%)	4/50 (8%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/40.02	4/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	2.5%	9.2%	0%	0%
TERMINAL (d)	1/29 (3%)	4/33 (12%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.109N	P=0.203	P=0.481N	P=0.638N
POLY 1.5	P=0.108N	P=0.196	P=0.487N	P=0.575N
POLY 6	P=0.103N	P=0.212	P=0.473N	P=0.713N
COCH-ARM / FISHERS	P=0.090N	P=0.181	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.179N	P=0.106	P=0.158N	P=0.324N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	14/50 (28%)	17/50 (34%)	19/50 (38%)	8/50 (16%)
POLY-3 RATE (b)	14/40.83	17/43.84	19/45.88	8/23.16
POLY-3 PERCENT (g)	34.3%	38.8%	41.4%	34.6%
TERMINAL (d)	12/29 (41%)	16/33 (49%)	14/31 (45%)	0/0 (0%)
FIRST INCIDENCE	521	596	551	480
STATISTICAL TESTS				
POLY 3	P=0.529	P=0.418	P=0.321	P=0.597
POLY 1.5	P=0.250N	P=0.395	P=0.272	P=0.331N
POLY 6	P=0.225	P=0.448	P=0.396	P=0.204
COCH-ARM / FISHERS	P=0.034N*	P=0.333	P=0.198	P=0.114N
MAX-ISO-POLY-3	P=0.614	P=0.336	P=0.258	P=0.493

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas				
Mineralization				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	2/44.34	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	4.5%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	556	---	---
STATISTICAL TESTS				
POLY 3	P=0.319N	P=0.261	(e)	(e)
POLY 1.5	P=0.328N	P=0.253	(e)	(e)
POLY 6	P=0.372N	P=0.270	(e)	(e)
COCH-ARM / FISHERS	P=0.326N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.510N	P=0.098	(e)	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas Necrosis				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	2/43.92	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	4.6%	0%	0%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	564	---	---
STATISTICAL TESTS				
POLY 3	P=0.319N	P=0.258	(e)	(e)
POLY 1.5	P=0.329N	P=0.252	(e)	(e)
POLY 6	P=0.371N	P=0.266	(e)	(e)
COCH-ARM / FISHERS	P=0.326N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.510N	P=0.096	(e)	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Parathyroid Gland Cyst				
LESION RATES				
OVERALL (a)	3/48 (6%)	1/43 (2%)	5/49 (10%)	0/44 (0%)
POLY-3 RATE (b)	3/39.43	1/37.80	5/43.29	0/16.19
POLY-3 PERCENT (g)	7.6%	2.7%	11.6%	0%
TERMINAL (d)	2/29 (7%)	1/30 (3%)	3/31 (10%)	0/0 (0%)
FIRST INCIDENCE	680	729 (T)	709	---
STATISTICAL TESTS				
POLY 3	P=0.552	P=0.320N	P=0.408	P=0.339N
POLY 1.5	P=0.390N	P=0.327N	P=0.396	P=0.225N
POLY 6	P=0.260	P=0.310N	P=0.426	P=0.522N
COCH-ARM / FISHERS	P=0.182N	P=0.351N	P=0.369	P=0.138N
MAX-ISO-POLY-3	P=0.435N	P=0.165N	P=0.282	P=0.227N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Peripheral Nerve Degeneration				
LESION RATES				
OVERALL (a)	2/2 (100%)	1/1 (100%)	1/1 (100%)	0/0 (0%)
POLY-3 RATE (b)	2/2.00	1/1.00	1/1.00	0/0.00
POLY-3 PERCENT (g)	100%	100%	100%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	598	556	612	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pituitary Gland: Pars Distalis Cyst				
LESION RATES				
OVERALL (a)	2/47 (4%)	2/43 (5%)	0/43 (0%)	1/44 (2%)
POLY-3 RATE (b)	2/37.99	2/37.41	0/38.02	1/16.54
POLY-3 PERCENT (g)	5.3%	5.4%	0%	6.1%
TERMINAL (d)	2/28 (7%)	2/29 (7%)	0/27 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	543
STATISTICAL TESTS				
POLY 3	P=0.425N	P=0.689	P=0.236N	P=0.676
POLY 1.5	P=0.443N	P=0.682	P=0.243N	P=0.650N
POLY 6	P=0.348N	P=0.692N	P=0.228N	P=0.503
COCH-ARM / FISHERS	P=0.396N	P=0.657	P=0.270N	P=0.525N
MAX-ISO-POLY-3	P=0.561N	P=0.493	P=0.080N	P=0.468

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Pituitary Gland: Pars Distalis
Hyperplasia

LESION RATES

OVERALL (a)	0/47 (0%)	0/43 (0%)	0/43 (0%)	0/44 (0%)
POLY-3 RATE (b)	0/37.99	0/37.41	0/38.02	0/15.95
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/28 (0%)	0/29 (0%)	0/27 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Pituitary Gland: Pars Distalis
Hyperplasia Focal

LESION RATES

OVERALL (a)	0/47 (0%)	1/43 (2%)	4/43 (9%)	1/44 (2%)
POLY-3 RATE (b)	0/37.99	1/37.96	4/38.02	1/16.54
POLY-3 PERCENT (g)	0%	2.6%	10.5%	6.1%
TERMINAL (d)	0/28 (0%)	0/29 (0%)	4/27 (15%)	0/0 (0%)
FIRST INCIDENCE	---	556	729 (T)	543

STATISTICAL TESTS

POLY 3	P=0.112	P=0.500	P=0.059	P=0.354
POLY 1.5	P=0.274	P=0.495	P=0.056	P=0.413
POLY 6	P=0.030*	P=0.506	P=0.063	P=0.284
COCH-ARM / FISHERS	P=0.538	P=0.478	P=0.048*	P=0.484
MAX-ISO-POLY-3	P=0.185	P=0.164	P=0.021*	P=0.151

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Preputial Gland Cyst				
<hr/>				
LESION RATES				
OVERALL (a)	9/50 (18%)	16/50 (32%)	14/50 (28%)	3/50 (6%)
POLY-3 RATE (b)	9/41.78	16/44.99	14/44.51	3/20.18
POLY-3 PERCENT (g)	21.5%	35.6%	31.5%	14.9%
TERMINAL (d)	4/29 (14%)	10/33 (30%)	11/31 (36%)	0/0 (0%)
FIRST INCIDENCE	491	603	656	477
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.278N	P=0.111	P=0.211	P=0.400N
POLY 1.5	P=0.072N	P=0.103	P=0.200	P=0.190N
POLY 6	P=0.452	P=0.126	P=0.228	P=0.479
COCH-ARM / FISHERS	P=0.005N**	P=0.083	P=0.171	P=0.061N
MAX-ISO-POLY-3	P=0.354N	P=0.079	P=0.155	P=0.329N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Preputial Gland Inflammation Acute				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/40.20	0/43.38	0/43.98	1/18.92
POLY-3 PERCENT (g)	5%	0%	0%	5.3%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	684	---	---	451
STATISTICAL TESTS				
POLY 3	P=0.598	P=0.220N	P=0.217N	P=0.695
POLY 1.5	P=0.611	P=0.225N	P=0.224N	P=0.626N
POLY 6	P=0.612N	P=0.215N	P=0.210N	P=0.516
COCH-ARM / FISHERS	P=0.692	P=0.247N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.428N	P=0.075N	P=0.075N	P=0.485

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Preputial Gland Inflammation Chronic				
LESION RATES				
OVERALL (a)	25/50 (50%)	29/50 (58%)	28/50 (56%)	5/50 (10%)
POLY-3 RATE (b)	25/43.26	29/47.68	28/46.91	5/21.12
POLY-3 PERCENT (g)	57.8%	60.8%	59.7%	23.7%
TERMINAL (d)	18/29 (62%)	18/33 (55%)	17/31 (55%)	0/0 (0%)
FIRST INCIDENCE	491	428	453	535
STATISTICAL TESTS				
POLY 3	P=0.022N*	P=0.467	P=0.512	P=0.010N**
POLY 1.5	P<0.001N**	P=0.402	P=0.455	P<0.001N**
POLY 6	P=0.353N	P=0.558	P=0.578N	P=0.295N
COCH-ARM / FISHERS	P<0.001N**	P=0.274	P=0.344	P<0.001N**
MAX-ISO-POLY-3	P=0.037N*	P=0.386	P=0.426	P=0.021N*

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Prostate Inflammation Acute				
LESION RATES				
OVERALL (a)	4/50 (8%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	4/41.85	2/44.22	1/44.16	0/18.16
POLY-3 PERCENT (g)	9.6%	4.5%	2.3%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	584	603	684	---
STATISTICAL TESTS				
POLY 3	P=0.132N	P=0.312N	P=0.162N	P=0.246N
POLY 1.5	P=0.104N	P=0.317N	P=0.166N	P=0.134N
POLY 6	P=0.168N	P=0.306N	P=0.158N	P=0.461N
COCH-ARM / FISHERS	P=0.061N	P=0.339N	P=0.181N	P=0.059N
MAX-ISO-POLY-3	P=0.217N	P=0.187N	P=0.079N	P=0.183N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Prostate Inflammation Chronic				
LESION RATES				
OVERALL (a)	27/50 (54%)	34/50 (68%)	30/50 (60%)	15/50 (30%)
POLY-3 RATE (b)	27/42.39	34/47.04	30/46.36	15/27.25
POLY-3 PERCENT (g)	63.7%	72.3%	64.7%	55%
TERMINAL (d)	22/29 (76%)	24/33 (73%)	22/31 (71%)	0/0 (0%)
FIRST INCIDENCE	494	428	453	451
STATISTICAL TESTS				
POLY 3	P=0.145N	P=0.249	P=0.551	P=0.305N
POLY 1.5	P=0.017N*	P=0.194	P=0.477	P=0.081N
POLY 6	P=0.530	P=0.344	P=0.534N	P=0.374
COCH-ARM / FISHERS	P<0.001N**	P=0.109	P=0.343	P=0.013N*
MAX-ISO-POLY-3	P=0.239N	P=0.192	P=0.460	P=0.256N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Prostate: Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	3/41.40	0/43.38	1/43.98	0/18.16
POLY-3 PERCENT (g)	7.3%	0%	2.3%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	584	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.318N	P=0.110N	P=0.283N	P=0.323N
POLY 1.5	P=0.268N	P=0.112N	P=0.289N	P=0.209N
POLY 6	P=0.437N	P=0.109N	P=0.277N	P=0.513N
COCH-ARM / FISHERS	P=0.197N	P=0.121N	P=0.309N	P=0.121N
MAX-ISO-POLY-3	P=0.282N	P=0.038N*	P=0.146N	P=0.218N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Salivary Glands Atrophy				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	5%	0%	0%	0%
TERMINAL (d)	2/29 (7%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.279N	P=0.219N	P=0.216N	P=0.434N
POLY 1.5	P=0.299N	P=0.225N	P=0.223N	P=0.333N
POLY 6	P=0.309N	P=0.213N	P=0.208N	P=0.582N
COCH-ARM / FISHERS	P=0.289N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.295N	P=0.075N	P=0.075N	P=0.258N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Salivary Glands				
Infiltration Cellular Mononuclear Cell				
LESION RATES				
OVERALL (a)	31/50 (62%)	38/50 (76%)	30/50 (60%)	21/50 (42%)
POLY-3 RATE (b)	31/44.16	38/47.14	30/47.30	21/30.76
POLY-3 PERCENT (g)	70.2%	80.6%	63.4%	68.3%
TERMINAL (d)	21/29 (72%)	29/33 (88%)	20/31 (65%)	0/0 (0%)
FIRST INCIDENCE	521	428	453	477
STATISTICAL TESTS				
POLY 3	P=0.209N	P=0.166	P=0.316N	P=0.534N
POLY 1.5	P=0.041N*	P=0.154	P=0.365N	P=0.194N
POLY 6	P=0.521	P=0.166	P=0.268N	P=0.191
COCH-ARM / FISHERS	P<0.001N**	P=0.097	P=0.500N	P=0.036N*
MAX-ISO-POLY-3	P=0.338N	P=0.116	P=0.248N	P=0.431N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Salivary Glands Mineralization				
LESION RATES				
OVERALL (a)	0/50 (0%)	5/50 (10%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	0/40.02	5/43.77	4/44.12	1/18.75
POLY-3 PERCENT (g)	0%	11.4%	9.1%	5.3%
TERMINAL (d)	0/29 (0%)	4/33 (12%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	---	618	709	538
STATISTICAL TESTS				
POLY 3	P=0.477	P=0.038*	P=0.073	P=0.365
POLY 1.5	P=0.513N	P=0.036*	P=0.069	P=0.427
POLY 6	P=0.320	P=0.042*	P=0.080	P=0.291
COCH-ARM / FISHERS	P=0.307N	P=0.028*	P=0.059	P=0.500
MAX-ISO-POLY-3	P=0.338	P=0.016*	P=0.030*	P=0.156

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Seminal Vesicle Inflammation Acute				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/49 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/40.49	1/43.98	0/43.04	0/17.85
POLY-3 PERCENT (g)	4.9%	2.3%	0%	0%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	592	540	---	---
STATISTICAL TESTS				
POLY 3	P=0.202N	P=0.471N	P=0.224N	P=0.440N
POLY 1.5	P=0.210N	P=0.479N	P=0.229N	P=0.339N
POLY 6	P=0.213N	P=0.462N	P=0.216N	P=0.586N
COCH-ARM / FISHERS	P=0.189N	P=0.500N	P=0.253N	P=0.253N
MAX-ISO-POLY-3	P=0.333N	P=0.264N	P=0.077N	P=0.262N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Seminal Vesicle Inflammation Chronic				
LESION RATES				
OVERALL (a)	3/50 (6%)	7/50 (14%)	8/49 (16%)	0/49 (0%)
POLY-3 RATE (b)	3/40.02	7/43.84	8/43.04	0/17.85
POLY-3 PERCENT (g)	7.5%	16%	18.6%	0%
TERMINAL (d)	3/29 (10%)	6/33 (18%)	8/31 (26%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	596	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.410N	P=0.195	P=0.120	P=0.318N
POLY 1.5	P=0.161N	P=0.184	P=0.111	P=0.209N
POLY 6	P=0.332	P=0.210	P=0.134	P=0.506N
COCH-ARM / FISHERS	P=0.034N*	P=0.159	P=0.094	P=0.125N
MAX-ISO-POLY-3	P=0.295N	P=0.126	P=0.074	P=0.212N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skeletal Muscle Fibrosis				
LESION RATES				
OVERALL (a)	2/2 (100%)	0/2 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	2/2.00	0/1.27	0/0.00	0/0.00
POLY-3 PERCENT (g)	100%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	598	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	P=0.010N**	(e)	(e)
POLY 1.5	(e)	P<0.001N**	(e)	(e)
POLY 6	(e)	P=0.270N	(e)	(e)
COCH-ARM / FISHERS	P=1.000N	P=0.167N	(e)	(e)
MAX-ISO-POLY-3	(e)	P<0.001N**	(e)	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skeletal Muscle Hemorrhage				
LESION RATES				
OVERALL (a)	2/2 (100%)	0/2 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	2/2.00	0/1.27	0/0.00	0/0.00
POLY-3 PERCENT (g)	100%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	598	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	P=0.010N**	(e)	(e)
POLY 1.5	(e)	P<0.001N**	(e)	(e)
POLY 6	(e)	P=0.270N	(e)	(e)
COCH-ARM / FISHERS	P=1.000N	P=0.167N	(e)	(e)
MAX-ISO-POLY-3	(e)	P<0.001N**	(e)	(e)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skeletal Muscle Inflammation Chronic				
LESION RATES				
OVERALL (a)	2/2 (100%)	0/2 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	2/2.00	0/1.27	0/0.00	0/0.00
POLY-3 PERCENT (g)	100%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	598	---	---	---
STATISTICAL TESTS				
POLY 3	(e)	P=0.010N**	(e)	(e)
POLY 1.5	(e)	P<0.001N**	(e)	(e)
POLY 6	(e)	P=0.270N	(e)	(e)
COCH-ARM / FISHERS	P=1.000N	P=0.167N	(e)	(e)
MAX-ISO-POLY-3	(e)	P<0.001N**	(e)	(e)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Cyst Epithelial Inclusion				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	1/44.16	0/18.16
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	684	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Skin				
Edema				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Fibrosis				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/40.02	1/43.38	0/43.98	1/18.74
POLY-3 PERCENT (g)	0%	2.3%	0%	5.3%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	---	543
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Skin				
Hemorrhage				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	1/18.74
POLY-3 PERCENT (g)	0%	0%	0%	5.3%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	543
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Hyperkeratosis				
LESION RATES				
OVERALL (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/40.96	3/43.38	0/43.98	1/18.74
POLY-3 PERCENT (g)	2.4%	6.9%	0%	5.3%
TERMINAL (d)	0/29 (0%)	3/33 (9%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	298	729 (T)	---	543
STATISTICAL TESTS				
POLY 3	P=0.432N	P=0.326	P=0.486N	P=0.568
POLY 1.5	P=0.448N	P=0.320	P=0.491N	P=0.665
POLY 6	P=0.358N	P=0.334	P=0.479N	P=0.428
COCH-ARM / FISHERS	P=0.401N	P=0.309	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.556N	P=0.175	P=0.158N	P=0.348

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Inflammation Acute				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	2/40.02	1/43.38	2/43.98	1/18.74
POLY-3 PERCENT (g)	5%	2.3%	4.6%	5.3%
TERMINAL (d)	2/29 (7%)	1/33 (3%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	543
STATISTICAL TESTS				
POLY 3	P=0.480	P=0.472N	P=0.660N	P=0.694
POLY 1.5	P=0.605	P=0.480N	P=0.671N	P=0.627N
POLY 6	P=0.460	P=0.462N	P=0.645N	P=0.515
COCH-ARM / FISHERS	P=0.494N	P=0.500N	P=0.691N	P=0.500N
MAX-ISO-POLY-3	P=0.655	P=0.265N	P=0.462N	P=0.484

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	3/50 (6%)	4/50 (8%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	3/41.13	4/43.82	0/43.98	3/19.92
POLY-3 PERCENT (g)	7.3%	9.1%	0%	15.1%
TERMINAL (d)	1/29 (3%)	3/33 (9%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	298	603	---	543
STATISTICAL TESTS				
POLY 3	P=0.544	P=0.535	P=0.107N	P=0.329
POLY 1.5	P=0.561	P=0.524	P=0.111N	P=0.482
POLY 6	P=0.464N	P=0.549	P=0.101N	P=0.164
COCH-ARM / FISHERS	P=0.546N	P=0.500	P=0.121N	P=0.661N
MAX-ISO-POLY-3	P=0.304	P=0.382	P=0.038N*	P=0.252

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin Mineralization				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	2/44.04	0/18.16
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	---	---	716	---
STATISTICAL TESTS				
POLY 3	P=0.330	(e)	P=0.259	(e)
POLY 1.5	P=0.555	(e)	P=0.252	(e)
POLY 6	P=0.139	(e)	P=0.269	(e)
COCH-ARM / FISHERS	P=0.693N	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.448	(e)	P=0.097	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Ulcer				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/40.66	1/43.38	1/43.98	1/18.74
POLY-3 PERCENT (g)	4.9%	2.3%	2.3%	5.3%
TERMINAL (d)	1/29 (3%)	1/33 (3%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	521	729 (T)	729 (T)	543
STATISTICAL TESTS				
POLY 3	P=0.585	P=0.477N	P=0.473N	P=0.690
POLY 1.5	P=0.601N	P=0.483N	P=0.481N	P=0.630N
POLY 6	P=0.664	P=0.470N	P=0.461N	P=0.511
COCH-ARM / FISHERS	P=0.508N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.617	P=0.268N	P=0.265N	P=0.480

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin: Lip				
Inflammation Acute				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/40.02	1/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	5%	2.3%	0%	0%
TERMINAL (d)	2/29 (7%)	1/33 (3%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.197N	P=0.472N	P=0.216N	P=0.434N
POLY 1.5	P=0.206N	P=0.480N	P=0.223N	P=0.333N
POLY 6	P=0.204N	P=0.462N	P=0.208N	P=0.582N
COCH-ARM / FISHERS	P=0.186N	P=0.500N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.323N	P=0.265N	P=0.075N	P=0.258N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Skin: Lip
Inflammation Chronic

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin: Prepuce				
Inflammation Acute				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	2/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	4.6%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.330	(e)	P=0.259	(e)
POLY 1.5	P=0.555	(e)	P=0.251	(e)
POLY 6	P=0.139	(e)	P=0.268	(e)
COCH-ARM / FISHERS	P=0.693N	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.448	(e)	P=0.096	(e)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Skin: Tail, Epidermis
Hyperkeratosis

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Skin: Tail, Epidermis
Hyperplasia

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	2/19.33
POLY-3 PERCENT (g)	0%	0%	0%	10.4%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	543

STATISTICAL TESTS

POLY 3	P=0.026*	(e)	(e)	P=0.121
POLY 1.5	P=0.026*	(e)	(e)	P=0.166
POLY 6	P=0.125	(e)	(e)	P=0.080
COCH-ARM / FISHERS	P=0.041*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.035*	(e)	(e)	P=0.072

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spinal Cord Degeneration				
LESION RATES				
OVERALL (a)	0/1 (0%)	0/1 (0%)	1/1 (100%)	0/0 (0%)
POLY-3 RATE (b)	0/0.56	0/0.44	1/1.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	100%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	612	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spleen				
Hematopoietic Cell Proliferation				
LESION RATES				
OVERALL (a)	14/50 (28%)	10/47 (21%)	13/47 (28%)	25/47 (53%)
POLY-3 RATE (b)	14/43.37	10/43.86	13/43.65	25/33.04
POLY-3 PERCENT (g)	32.3%	22.8%	29.8%	75.7%
TERMINAL (d)	8/29 (28%)	5/33 (15%)	7/31 (23%)	0/0 (0%)
FIRST INCIDENCE	298	564	453	3
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.225N	P=0.492N	P<0.001**
POLY 1.5	P<0.001**	P=0.247N	P=0.519N	P<0.001**
POLY 6	P<0.001**	P=0.198N	P=0.454N	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.298N	P=0.575N	P=0.010**
MAX-ISO-POLY-3	P<0.001**	P=0.165N	P=0.400N	P<0.001**

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spleen Pigmentation				
LESION RATES				
OVERALL (a)	13/50 (26%)	12/47 (26%)	2/47 (4%)	2/47 (4%)
POLY-3 RATE (b)	13/43.12	12/44.36	2/42.01	2/18.50
POLY-3 PERCENT (g)	30.2%	27.1%	4.8%	10.8%
TERMINAL (d)	5/29 (17%)	6/33 (18%)	2/31 (7%)	0/0 (0%)
FIRST INCIDENCE	521	556	729 (T)	543
STATISTICAL TESTS				
POLY 3	P=0.008N**	P=0.467N	P=0.002N**	P=0.124N
POLY 1.5	P=0.004N**	P=0.495N	P=0.002N**	P=0.026N*
POLY 6	P=0.005N**	P=0.440N	P=0.002N**	P=0.483N
COCH-ARM / FISHERS	P<0.001N**	P=0.572N	P=0.003N**	P=0.003N**
MAX-ISO-POLY-3	P=0.013N*	P=0.376N	P<0.001N**	P=0.132N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Spleen: Lymphoid Follicle Atrophy

LESION RATES

OVERALL (a)	1/50 (2%)	2/47 (4%)	3/47 (6%)	4/47 (9%)
POLY-3 RATE (b)	1/40.47	2/42.36	3/42.46	4/20.06
POLY-3 PERCENT (g)	2.5%	4.7%	7.1%	19.9%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	598	698	618	442

STATISTICAL TESTS

POLY 3	P=0.030*	P=0.516	P=0.322	P=0.046*
POLY 1.5	P=0.058	P=0.504	P=0.309	P=0.084
POLY 6	P=0.030*	P=0.529	P=0.339	P=0.018*
COCH-ARM / FISHERS	P=0.140	P=0.477	P=0.285	P=0.162
MAX-ISO-POLY-3	P=0.049*	P=0.300	P=0.175	P=0.044*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spleen: Lymphoid Follicle Hyperplasia				
LESION RATES				
OVERALL (a)	11/50 (22%)	7/47 (15%)	9/47 (19%)	5/47 (11%)
POLY-3 RATE (b)	11/40.20	7/42.24	9/42.18	5/20.69
POLY-3 PERCENT (g)	27.4%	16.6%	21.3%	24.2%
TERMINAL (d)	10/29 (35%)	7/33 (21%)	8/31 (26%)	0/0 (0%)
FIRST INCIDENCE	684	729 (T)	684	3
STATISTICAL TESTS				
POLY 3	P=0.499	P=0.177N	P=0.351N	P=0.514N
POLY 1.5	P=0.389N	P=0.203N	P=0.388N	P=0.273N
POLY 6	P=0.337	P=0.151N	P=0.306N	P=0.335
COCH-ARM / FISHERS	P=0.143N	P=0.262N	P=0.463N	P=0.108N
MAX-ISO-POLY-3	P=0.525N	P=0.126N	P=0.269N	P=0.418N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spleen: Lymphoid Follicle Hyperplasia Focal				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/47 (0%)	0/47 (0%)	0/47 (0%)
POLY-3 RATE (b)	0/40.02	0/42.24	0/42.01	0/17.33
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Edema				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	2/45.50	0/18.16
POLY-3 PERCENT (g)	0%	0%	4.4%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	453	---
STATISTICAL TESTS				
POLY 3	P=0.330	(e)	P=0.267	(e)
POLY 1.5	P=0.553	(e)	P=0.257	(e)
POLY 6	P=0.143	(e)	P=0.279	(e)
COCH-ARM / FISHERS	P=0.693N	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.456	(e)	P=0.104	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Erosion				
LESION RATES				
OVERALL (a)	4/50 (8%)	5/50 (10%)	9/50 (18%)	3/50 (6%)
POLY-3 RATE (b)	4/40.28	5/44.18	9/45.56	3/19.93
POLY-3 PERCENT (g)	9.9%	11.3%	19.8%	15.1%
TERMINAL (d)	3/29 (10%)	2/33 (6%)	6/31 (19%)	0/0 (0%)
FIRST INCIDENCE	660	556	453	537
STATISTICAL TESTS				
POLY 3	P=0.226	P=0.558	P=0.167	P=0.444
POLY 1.5	P=0.478	P=0.540	P=0.149	P=0.617
POLY 6	P=0.078	P=0.580	P=0.190	P=0.225
COCH-ARM / FISHERS	P=0.327N	P=0.500	P=0.117	P=0.500N
MAX-ISO-POLY-3	P=0.370	P=0.420	P=0.115	P=0.339

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Fibrosis				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/40.50	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	4.9%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	598	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.278N	P=0.222N	P=0.219N	P=0.437N
POLY 1.5	P=0.298N	P=0.226N	P=0.225N	P=0.335N
POLY 6	P=0.306N	P=0.218N	P=0.212N	P=0.584N
COCH-ARM / FISHERS	P=0.289N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.299N	P=0.075N	P=0.075N	P=0.260N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Foreign Body				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	2/44.37	0/18.16
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	---	---	618	---
STATISTICAL TESTS				
POLY 3	P=0.330	(e)	P=0.261	(e)
POLY 1.5	P=0.555	(e)	P=0.253	(e)
POLY 6	P=0.140	(e)	P=0.272	(e)
COCH-ARM / FISHERS	P=0.693N	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.450	(e)	P=0.098	(e)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Inflammation				
LESION RATES				
OVERALL (a)	18/50 (36%)	18/50 (36%)	34/50 (68%)	19/50 (38%)
POLY-3 RATE (b)	18/44.17	18/45.35	34/47.23	19/29.75
POLY-3 PERCENT (g)	40.8%	39.7%	72%	63.9%
TERMINAL (d)	7/29 (24%)	11/33 (33%)	22/31 (71%)	0/0 (0%)
FIRST INCIDENCE	521	556	453	480
STATISTICAL TESTS				
POLY 3	P=0.005**	P=0.545N	P<0.001**	P=0.038*
POLY 1.5	P=0.071	P=0.542N	P<0.001**	P=0.169
POLY 6	P<0.001**	P=0.556N	P=0.002**	P=0.002**
COCH-ARM / FISHERS	P=0.529	P=0.582N	P<0.001**	P=0.500
MAX-ISO-POLY-3	P=0.009**	P=0.458N	P<0.001**	P=0.042*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	0/43.38	0/43.98	0/18.16
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Ulcer				
LESION RATES				
OVERALL (a)	9/50 (18%)	8/50 (16%)	14/50 (28%)	11/50 (22%)
POLY-3 RATE (b)	9/42.13	8/45.05	14/45.77	11/24.95
POLY-3 PERCENT (g)	21.4%	17.8%	30.6%	44.1%
TERMINAL (d)	3/29 (10%)	3/33 (9%)	7/31 (23%)	0/0 (0%)
FIRST INCIDENCE	568	428	453	480
STATISTICAL TESTS				
POLY 3	P=0.016*	P=0.439N	P=0.229	P=0.048*
POLY 1.5	P=0.068	P=0.453N	P=0.211	P=0.157
POLY 6	P=0.003**	P=0.427N	P=0.253	P=0.005**
COCH-ARM / FISHERS	P=0.314	P=0.500N	P=0.171	P=0.402
MAX-ISO-POLY-3	P=0.026*	P=0.340N	P=0.172	P=0.056

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach: Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	26/50 (52%)	19/50 (38%)	40/50 (80%)	29/50 (58%)
POLY-3 RATE (b)	26/45.54	19/45.42	40/48.15	29/35.92
POLY-3 PERCENT (g)	57.1%	41.8%	83.1%	80.7%
TERMINAL (d)	12/29 (41%)	12/33 (36%)	24/31 (77%)	0/0 (0%)
FIRST INCIDENCE	521	556	453	442
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.102N	P=0.004**	P=0.014*
POLY 1.5	P=0.004**	P=0.094N	P=0.003**	P=0.080
POLY 6	P<0.001**	P=0.121N	P=0.004**	P<0.001**
COCH-ARM / FISHERS	P=0.120	P=0.114N	P=0.003**	P=0.344
MAX-ISO-POLY-3	P<0.001**	P=0.069N	P=0.002**	P=0.013*

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Glandular Erosion				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/48 (0%)	1/48 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/40.02	0/42.37	1/42.89	2/19.54
POLY-3 PERCENT (g)	0%	0%	2.3%	10.2%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	715	451
STATISTICAL TESTS				
POLY 3	P=0.029*	(e)	P=0.514	P=0.122
POLY 1.5	P=0.045*	(e)	P=0.506	P=0.167
POLY 6	P=0.055	(e)	P=0.523	P=0.081
COCH-ARM / FISHERS	P=0.088	(e)	P=0.490	P=0.247
MAX-ISO-POLY-3	P=0.048*	(e)	P=0.178	P=0.072

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Glandular Inflammation				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/48 (2%)	2/48 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/40.28	1/43.16	2/43.22	0/18.16
POLY-3 PERCENT (g)	2.5%	2.3%	4.6%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	660	428	618	---
STATISTICAL TESTS				
POLY 3	P=0.611N	P=0.745N	P=0.525	P=0.639N
POLY 1.5	P=0.471N	P=0.753N	P=0.512	P=0.576N
POLY 6	P=0.502	P=0.737N	P=0.540	P=0.713N
COCH-ARM / FISHERS	P=0.325N	P=0.742	P=0.485	P=0.500N
MAX-ISO-POLY-3	P=0.544N	P=0.480N	P=0.309	P=0.325N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Glandular Mineralization				
LESION RATES				
OVERALL (a)	4/50 (8%)	5/48 (10%)	6/48 (13%)	2/50 (4%)
POLY-3 RATE (b)	4/40.50	5/42.52	6/43.18	2/19.33
POLY-3 PERCENT (g)	9.9%	11.8%	13.9%	10.4%
TERMINAL (d)	2/29 (7%)	4/33 (12%)	4/31 (13%)	0/0 (0%)
FIRST INCIDENCE	598	689	684	543
STATISTICAL TESTS				
POLY 3	P=0.498	P=0.531	P=0.410	P=0.639
POLY 1.5	P=0.428N	P=0.514	P=0.388	P=0.518N
POLY 6	P=0.330	P=0.551	P=0.438	P=0.396
COCH-ARM / FISHERS	P=0.189N	P=0.474	P=0.344	P=0.339N
MAX-ISO-POLY-3	P=0.649	P=0.393	P=0.294	P=0.483

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Glandular Ulcer				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/48 (0%)	2/48 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/40.28	0/42.37	2/43.11	1/18.77
POLY-3 PERCENT (g)	2.5%	0%	4.6%	5.3%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	660	---	656	530
STATISTICAL TESTS				
POLY 3	P=0.226	P=0.490N	P=0.524	P=0.572
POLY 1.5	P=0.352	P=0.495N	P=0.511	P=0.668
POLY 6	P=0.181	P=0.484N	P=0.539	P=0.430
COCH-ARM / FISHERS	P=0.546	P=0.510N	P=0.485	P=0.753N
MAX-ISO-POLY-3	P=0.370	P=0.161N	P=0.307	P=0.350

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Stomach, Glandular: Glands
Ectasia Focal

LESION RATES

OVERALL (a)	0/50 (0%)	1/48 (2%)	2/48 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/40.02	1/42.37	2/43.40	0/18.16
POLY-3 PERCENT (g)	0%	2.4%	4.6%	0%
TERMINAL (d)	0/29 (0%)	1/33 (3%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	551	---

STATISTICAL TESTS

POLY 3	P=0.508	P=0.511	P=0.256	(e)
POLY 1.5	P=0.630N	P=0.505	P=0.246	(e)
POLY 6	P=0.324	P=0.519	P=0.268	(e)
COCH-ARM / FISHERS	P=0.484N	P=0.490	P=0.237	(e)
MAX-ISO-POLY-3	P=0.505	P=0.175	P=0.095	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Testes				
Giant Cell				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	4/50 (8%)	2/49 (4%)
POLY-3 RATE (b)	2/40.91	0/43.38	4/44.29	2/19.26
POLY-3 PERCENT (g)	4.9%	0%	9%	10.4%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	569	---	684	477
STATISTICAL TESTS				
POLY 3	P=0.096	P=0.224N	P=0.374	P=0.415
POLY 1.5	P=0.207	P=0.227N	P=0.363	P=0.546
POLY 6	P=0.049*	P=0.221N	P=0.389	P=0.253
COCH-ARM / FISHERS	P=0.423	P=0.247N	P=0.339	P=0.684
MAX-ISO-POLY-3	P=0.159	P=0.075N	P=0.238	P=0.291

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Testes: Germinal Epithelium Atrophy				
LESION RATES				
OVERALL (a)	11/50 (22%)	8/50 (16%)	20/50 (40%)	13/49 (27%)
POLY-3 RATE (b)	11/42.69	8/43.62	20/45.73	13/26.13
POLY-3 PERCENT (g)	25.8%	18.3%	43.7%	49.8%
TERMINAL (d)	4/29 (14%)	6/33 (18%)	12/31 (39%)	0/0 (0%)
FIRST INCIDENCE	494	689	453	442
STATISTICAL TESTS				
POLY 3	P=0.004**	P=0.283N	P=0.057	P=0.039*
POLY 1.5	P=0.032*	P=0.282N	P=0.053	P=0.140
POLY 6	P<0.001**	P=0.288N	P=0.065	P=0.003**
COCH-ARM / FISHERS	P=0.238	P=0.306N	P=0.041*	P=0.385
MAX-ISO-POLY-3	P=0.007**	P=0.205N	P=0.040*	P=0.046*

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thymus Atrophy				
LESION RATES				
OVERALL (a)	26/40 (65%)	28/41 (68%)	23/40 (58%)	23/39 (59%)
POLY-3 RATE (b)	26/38.89	28/40.45	23/39.26	23/29.40
POLY-3 PERCENT (g)	66.9%	69.2%	58.6%	78.2%
TERMINAL (d)	13/25 (52%)	15/27 (56%)	10/25 (40%)	0/0 (0%)
FIRST INCIDENCE	3	428	453	3
STATISTICAL TESTS				
POLY 3	P=0.240	P=0.505	P=0.302N	P=0.209
POLY 1.5	P=0.497	P=0.501	P=0.301N	P=0.489
POLY 6	P=0.068	P=0.503	P=0.310N	P=0.031*
COCH-ARM / FISHERS	P=0.263N	P=0.469	P=0.323N	P=0.375N
MAX-ISO-POLY-3	P=0.256	P=0.410	P=0.227N	P=0.165

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thymus Cyst				
LESION RATES				
OVERALL (a)	14/40 (35%)	12/41 (29%)	13/40 (33%)	3/39 (8%)
POLY-3 RATE (b)	14/34.95	12/36.43	13/36.48	3/16.04
POLY-3 PERCENT (g)	40.1%	32.9%	35.6%	18.7%
TERMINAL (d)	10/25 (40%)	9/27 (33%)	9/25 (36%)	0/0 (0%)
FIRST INCIDENCE	494	564	627	543
STATISTICAL TESTS				
POLY 3	P=0.192N	P=0.352N	P=0.444N	P=0.138N
POLY 1.5	P=0.049N*	P=0.346N	P=0.449N	P=0.027N*
POLY 6	P=0.507N	P=0.361N	P=0.442N	P=0.538N
COCH-ARM / FISHERS	P=0.003N**	P=0.377N	P=0.500N	P=0.003N**
MAX-ISO-POLY-3	P=0.281N	P=0.268N	P=0.351N	P=0.140N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thymus Hyperplasia Lymphoid				
LESION RATES				
OVERALL (a)	1/40 (3%)	2/41 (5%)	3/40 (8%)	1/39 (3%)
POLY-3 RATE (b)	1/33.09	2/35.37	3/35.68	1/14.87
POLY-3 PERCENT (g)	3%	5.7%	8.4%	6.7%
TERMINAL (d)	0/25 (0%)	2/27 (7%)	3/25 (12%)	0/0 (0%)
FIRST INCIDENCE	680	729 (T)	729 (T)	543
STATISTICAL TESTS				
POLY 3	P=0.366	P=0.523	P=0.332	P=0.564
POLY 1.5	P=0.535	P=0.522	P=0.326	P=0.660
POLY 6	P=0.257	P=0.523	P=0.335	P=0.426
COCH-ARM / FISHERS	P=0.510N	P=0.509	P=0.308	P=0.747
MAX-ISO-POLY-3	P=0.544	P=0.304	P=0.181	P=0.345

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thymus				
Necrosis Lymphoid				
LESION RATES				
OVERALL (a)	0/40 (0%)	6/41 (15%)	3/40 (8%)	3/39 (8%)
POLY-3 RATE (b)	0/32.90	6/37.98	3/36.94	3/16.96
POLY-3 PERCENT (g)	0%	15.8%	8.1%	17.7%
TERMINAL (d)	0/25 (0%)	0/27 (0%)	0/25 (0%)	0/0 (0%)
FIRST INCIDENCE	---	428	581	3
STATISTICAL TESTS				
POLY 3	P=0.258	P=0.023*	P=0.139	P=0.041*
POLY 1.5	P=0.381	P=0.020*	P=0.133	P=0.069
POLY 6	P=0.250	P=0.026*	P=0.147	P=0.021*
COCH-ARM / FISHERS	P=0.556	P=0.014*	P=0.120	P=0.116
MAX-ISO-POLY-3	P=0.153	P=0.011*	P=0.056	P=0.032*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Thyroid Gland: Follicle
Cyst

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	1/50 (2%)	1/49 (2%)
POLY-3 RATE (b)	0/40.02	0/42.85	1/43.98	1/18.74
POLY-3 PERCENT (g)	0%	0%	2.3%	5.3%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	1/31 (3%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	543

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thyroid Gland: Follicle Degeneration				
LESION RATES				
OVERALL (a)	21/50 (42%)	19/49 (39%)	12/50 (24%)	6/49 (12%)
POLY-3 RATE (b)	21/43.73	19/45.51	12/45.13	6/21.94
POLY-3 PERCENT (g)	48%	41.8%	26.6%	27.4%
TERMINAL (d)	12/29 (41%)	13/33 (39%)	7/31 (23%)	0/0 (0%)
FIRST INCIDENCE	568	540	551	477
STATISTICAL TESTS				
POLY 3	P=0.040N*	P=0.350N	P=0.027N*	P=0.098N
POLY 1.5	P=0.008N**	P=0.372N	P=0.030N*	P=0.011N*
POLY 6	P=0.115N	P=0.332N	P=0.026N*	P=0.579N
COCH-ARM / FISHERS	P<0.001N**	P=0.452N	P=0.044N*	P<0.001N**
MAX-ISO-POLY-3	P=0.066N	P=0.279N	P=0.017N*	P=0.109N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thyroid Gland: Follicle Hypertrophy				
LESION RATES				
OVERALL (a)	25/50 (50%)	35/49 (71%)	41/50 (82%)	45/49 (92%)
POLY-3 RATE (b)	25/42.70	35/45.50	41/47.94	45/46.19
POLY-3 PERCENT (g)	58.5%	76.9%	85.5%	97.4%
TERMINAL (d)	19/29 (66%)	28/33 (85%)	27/31 (87%)	0/0 (0%)
FIRST INCIDENCE	491	540	431	442
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.042*	P=0.002**	P<0.001**
POLY 1.5	P<0.001**	P=0.036*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.053	P=0.004**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.024*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.028*	P<0.001**	P<0.001**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Urethra				
Inflammation Acute				
LESION RATES				
OVERALL (a)	0/0 (0%)	2/4 (50%)	2/3 (67%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	2/3.15	2/2.64	0/0.00
POLY-3 PERCENT (g)	0%	63.5%	75.9%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	428	581	---
STATISTICAL TESTS				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.941	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Urethra: Bulbourethral Gland
Necrosis

LESION RATES

OVERALL (a)	0/0 (0%)	2/4 (50%)	1/3 (33%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	2/3.10	1/2.14	0/0.00
POLY-3 PERCENT (g)	0%	64.5%	46.7%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	428	715	---

STATISTICAL TESTS

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.941N	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Urinary Bladder Hemorrhage				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/49 (2%)	1/48 (2%)	0/48 (0%)
POLY-3 RATE (b)	2/40.91	1/43.57	1/42.62	0/17.57
POLY-3 PERCENT (g)	4.9%	2.3%	2.4%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	600	428	581	---
STATISTICAL TESTS				
POLY 3	P=0.350N	P=0.478N	P=0.486N	P=0.446N
POLY 1.5	P=0.292N	P=0.486N	P=0.495N	P=0.345N
POLY 6	P=0.486N	P=0.470N	P=0.474N	P=0.590N
COCH-ARM / FISHERS	P=0.214N	P=0.508N	P=0.515N	P=0.258N
MAX-ISO-POLY-3	P=0.435N	P=0.269N	P=0.274N	P=0.267N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Urinary Bladder Inflammation Acute				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/49 (2%)	1/48 (2%)	0/48 (0%)
POLY-3 RATE (b)	2/40.45	1/43.18	1/42.62	0/17.57
POLY-3 PERCENT (g)	4.9%	2.3%	2.4%	0%
TERMINAL (d)	1/29 (3%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	606	614	581	---
STATISTICAL TESTS				
POLY 3	P=0.347N	P=0.477N	P=0.482N	P=0.443N
POLY 1.5	P=0.290N	P=0.486N	P=0.492N	P=0.344N
POLY 6	P=0.482N	P=0.466N	P=0.468N	P=0.588N
COCH-ARM / FISHERS	P=0.214N	P=0.508N	P=0.515N	P=0.258N
MAX-ISO-POLY-3	P=0.431N	P=0.269N	P=0.272N	P=0.264N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Urinary Bladder Necrosis				
LESION RATES				
OVERALL (a)	1/50 (2%)	3/49 (6%)	3/48 (6%)	0/48 (0%)
POLY-3 RATE (b)	1/40.47	3/43.99	3/43.16	0/17.57
POLY-3 PERCENT (g)	2.5%	6.8%	7%	0%
TERMINAL (d)	0/29 (0%)	0/33 (0%)	0/31 (0%)	0/0 (0%)
FIRST INCIDENCE	600	603	581	---
STATISTICAL TESTS				
POLY 3	P=0.496N	P=0.336	P=0.328	P=0.645N
POLY 1.5	P=0.332N	P=0.323	P=0.315	P=0.583N
POLY 6	P=0.523	P=0.352	P=0.347	P=0.717N
COCH-ARM / FISHERS	P=0.181N	P=0.301	P=0.293	P=0.510N
MAX-ISO-POLY-3	P=0.479N	P=0.186	P=0.180	P=0.330N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex				
Accessory Adrenal Cortical Nodule				
LESION RATES				
OVERALL (a)	5/50 (10%)	5/50 (10%)	1/49 (2%)	3/47 (6%)
POLY-3 RATE (b)	5/44.19	5/44.71	1/44.67	3/20.72
POLY-3 PERCENT (g)	11.3%	11.2%	2.2%	14.5%
TERMINAL (d)	3/33 (9%)	3/35 (9%)	1/36 (3%)	0/0 (0%)
FIRST INCIDENCE	579	684	729 (T)	459
STATISTICAL TESTS				
POLY 3	P=0.452N	P=0.623N	P=0.098N	P=0.515
POLY 1.5	P=0.422N	P=0.620N	P=0.101N	P=0.584N
POLY 6	P=0.380N	P=0.625N	P=0.096N	P=0.265
COCH-ARM / FISHERS	P=0.309N	P=0.630N	P=0.107N	P=0.393N
MAX-ISO-POLY-3	P=0.481	P=0.491N	P=0.044N*	P=0.398

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex Degeneration Fatty				
LESION RATES				
OVERALL (a)	3/50 (6%)	2/50 (4%)	3/49 (6%)	0/47 (0%)
POLY-3 RATE (b)	3/43.26	2/44.47	3/44.67	0/18.79
POLY-3 PERCENT (g)	6.9%	4.5%	6.7%	0%
TERMINAL (d)	3/33 (9%)	2/35 (6%)	3/36 (8%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.363N	P=0.487N	P=0.648N	P=0.324N
POLY 1.5	P=0.236N	P=0.488N	P=0.656N	P=0.213N
POLY 6	P=0.617N	P=0.485N	P=0.637N	P=0.510N
COCH-ARM / FISHERS	P=0.125N	P=0.500N	P=0.651	P=0.133N
MAX-ISO-POLY-3	P=0.404N	P=0.315N	P=0.483N	P=0.217N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex				
Hematopoietic Cell Proliferation				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	2/49 (4%)	1/47 (2%)
POLY-3 RATE (b)	0/43.26	2/44.92	2/45.72	1/19.39
POLY-3 PERCENT (g)	0%	4.5%	4.4%	5.2%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	---	618	563	535
STATISTICAL TESTS				
POLY 3	P=0.324	P=0.246	P=0.250	P=0.358
POLY 1.5	P=0.467	P=0.244	P=0.243	P=0.420
POLY 6	P=0.278	P=0.248	P=0.258	P=0.286
COCH-ARM / FISHERS	P=0.635	P=0.247	P=0.242	P=0.485
MAX-ISO-POLY-3	P=0.417	P=0.084	P=0.089	P=0.152

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex Hemorrhage				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/49 (0%)	2/47 (4%)
POLY-3 RATE (b)	1/43.26	0/44.47	0/44.67	2/20.23
POLY-3 PERCENT (g)	2.3%	0%	0%	9.9%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	432
STATISTICAL TESTS				
POLY 3	P=0.110	P=0.494N	P=0.494N	P=0.270
POLY 1.5	P=0.120	P=0.495N	P=0.497N	P=0.367
POLY 6	P=0.288	P=0.493N	P=0.489N	P=0.167
COCH-ARM / FISHERS	P=0.159	P=0.500N	P=0.505N	P=0.477
MAX-ISO-POLY-3	P=0.097	P=0.158N	P=0.160N	P=0.178

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex Hyperplasia				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	4/49 (8%)	0/47 (0%)
POLY-3 RATE (b)	1/43.26	0/44.47	4/44.67	0/18.79
POLY-3 PERCENT (g)	2.3%	0%	9%	0%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	4/36 (11%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.306	P=0.494N	P=0.188	P=0.645N
POLY 1.5	P=0.585	P=0.495N	P=0.183	P=0.582N
POLY 6	P=0.072	P=0.493N	P=0.195	P=0.717N
COCH-ARM / FISHERS	P=0.472N	P=0.500N	P=0.175	P=0.515N
MAX-ISO-POLY-3	P=0.422	P=0.158N	P=0.094	P=0.329N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex				
Hypertrophy Diffuse				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	4/49 (8%)	8/47 (17%)
POLY-3 RATE (b)	0/43.26	0/44.47	4/45.12	8/23.84
POLY-3 PERCENT (g)	0%	0%	8.9%	33.6%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	3/36 (8%)	0/0 (0%)
FIRST INCIDENCE	---	---	598	432
STATISTICAL TESTS				
POLY 3	P<0.001**	(e)	P=0.066	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.063	P<0.001**
POLY 6	P<0.001**	(e)	P=0.069	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.056	P=0.002**
MAX-ISO-POLY-3	P<0.001**	(e)	P=0.024*	P<0.001**

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Adrenal Cortex				
Hypertrophy Focal				
LESION RATES				
OVERALL (a)	7/50 (14%)	4/50 (8%)	9/49 (18%)	2/47 (4%)
POLY-3 RATE (b)	7/43.73	4/44.47	9/44.67	2/19.97
POLY-3 PERCENT (g)	16%	9%	20.2%	10%
TERMINAL (d)	6/33 (18%)	4/35 (11%)	9/36 (25%)	0/0 (0%)
FIRST INCIDENCE	589	729 (T)	729 (T)	542
STATISTICAL TESTS				
POLY 3	P=0.470	P=0.250N	P=0.410	P=0.413N
POLY 1.5	P=0.376N	P=0.250N	P=0.398	P=0.221N
POLY 6	P=0.198	P=0.250N	P=0.423	P=0.538
COCH-ARM / FISHERS	P=0.137N	P=0.262N	P=0.376	P=0.095N
MAX-ISO-POLY-3	P=0.546N	P=0.162N	P=0.310	P=0.329N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Adrenal Cortex: Capsule
Hyperplasia

LESION RATES

OVERALL (a)	49/50 (98%)	50/50 (100%)	47/49 (96%)	47/47 (100%)
POLY-3 RATE (b)	49/49.00	50/50.00	47/48.00	47/47.00
POLY-3 PERCENT (g)	100%	100%	97.9%	100%
TERMINAL (d)	33/33 (100%)	35/35 (100%)	35/36 (97%)	0/0 (0%)
FIRST INCIDENCE	340	421	535	432

STATISTICAL TESTS

POLY 3	P=0.793	P=1.000	P=0.496N	P=1.000
POLY 1.5	P=0.793	P=1.000	P=0.496N	P=1.000
POLY 6	P=0.793	P=0.500	P=0.496N	P=0.515
COCH-ARM / FISHERS	P=0.490	P=0.500	P=0.492N	P=0.515
MAX-ISO-POLY-3	P=0.388N	P=0.161	P=0.158N	P=0.168

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Bone Marrow: Myeloid Cell Hyperplasia				
LESION RATES				
OVERALL (a)	1/49 (2%)	3/50 (6%)	1/50 (2%)	0/49 (0%)
POLY-3 RATE (b)	1/42.56	3/44.86	1/46.18	0/19.47
POLY-3 PERCENT (g)	2.4%	6.7%	2.2%	0%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	684	618	575	---
STATISTICAL TESTS				
POLY 3	P=0.260N	P=0.324	P=0.742N	P=0.637N
POLY 1.5	P=0.212N	P=0.323	P=0.747N	P=0.572N
POLY 6	P=0.370N	P=0.326	P=0.737N	P=0.712N
COCH-ARM / FISHERS	P=0.151N	P=0.316	P=0.747N	P=0.500N
MAX-ISO-POLY-3	P=0.422N	P=0.173	P=0.476N	P=0.323N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Bone
Fibro-osseous Lesion

LESION RATES

OVERALL (a)	43/49 (88%)	46/50 (92%)	49/50 (98%)	43/50 (86%)
POLY-3 RATE (b)	43/46.89	46/48.56	49/49.49	43/45.56
POLY-3 PERCENT (g)	91.7%	94.7%	99%	94.4%
TERMINAL (d)	32/33 (97%)	34/35 (97%)	37/37 (100%)	0/0 (0%)
FIRST INCIDENCE	340	421	3	366

STATISTICAL TESTS

POLY 3	P=0.510	P=0.419	P=0.081	P=0.453
POLY 1.5	P=0.478N	P=0.439	P=0.084	P=0.633
POLY 6	P=0.228	P=0.415	P=0.089	P=0.242
COCH-ARM / FISHERS	P=0.259N	P=0.357	P=0.053	P=0.516N
MAX-ISO-POLY-3	P=0.152	P=0.258	P=0.028*	P=0.274

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Bone: Tail Callus				
LESION RATES				
OVERALL (a)	1/49 (2%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/42.51	0/44.47	2/46.44	1/20.39
POLY-3 PERCENT (g)	2.4%	0%	4.3%	4.9%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	697	---	535	432
STATISTICAL TESTS				
POLY 3	P=0.234	P=0.491N	P=0.531	P=0.579
POLY 1.5	P=0.370	P=0.491N	P=0.522	P=0.679
POLY 6	P=0.188	P=0.491N	P=0.541	P=0.433
COCH-ARM / FISHERS	P=0.543	P=0.495N	P=0.508	P=0.747N
MAX-ISO-POLY-3	P=0.383	P=0.157N	P=0.313	P=0.354

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Bone: Tail				
Developmental Malformation				
<hr/>				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.39	0/44.47	1/45.67	0/19.60
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Bone: Vertebra Callus				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.39	0/44.47	1/46.12	0/19.60
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	598	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Brain Compression				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/49 (0%)
POLY-3 RATE (b)	1/43.26	2/44.53	1/45.67	0/19.23
POLY-3 PERCENT (g)	2.3%	4.5%	2.2%	0%
TERMINAL (d)	1/33 (3%)	1/35 (3%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	715	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.351N	P=0.510	P=0.748N	P=0.641N
POLY 1.5	P=0.295N	P=0.509	P=0.753N	P=0.577N
POLY 6	P=0.498N	P=0.512	P=0.743N	P=0.715N
COCH-ARM / FISHERS	P=0.222N	P=0.500	P=0.753N	P=0.505N
MAX-ISO-POLY-3	P=0.510N	P=0.292	P=0.484N	P=0.327N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Brain Hemorrhage				
LESION RATES				
OVERALL (a)	3/50 (6%)	1/50 (2%)	3/50 (6%)	1/49 (2%)
POLY-3 RATE (b)	3/43.83	1/44.94	3/46.29	1/19.82
POLY-3 PERCENT (g)	6.9%	2.2%	6.5%	5.1%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	601	590	535	542
STATISTICAL TESTS				
POLY 3	P=0.501	P=0.296N	P=0.637N	P=0.597N
POLY 1.5	P=0.545N	P=0.297N	P=0.646N	P=0.455N
POLY 6	P=0.408	P=0.295N	P=0.628N	P=0.564
COCH-ARM / FISHERS	P=0.375N	P=0.309N	P=0.661N	P=0.316N
MAX-ISO-POLY-3	P=0.631N	P=0.150N	P=0.472N	P=0.425N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Brain				
Infiltration Cellular Mononuclear Cell				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	1/49 (2%)
POLY-3 RATE (b)	1/43.26	1/44.47	1/45.81	1/19.82
POLY-3 PERCENT (g)	2.3%	2.3%	2.2%	5.1%
TERMINAL (d)	1/33 (3%)	1/35 (3%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	695	542
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Clitoral Gland Inflammation Chronic				
LESION RATES				
OVERALL (a)	5/49 (10%)	13/49 (27%)	8/50 (16%)	18/50 (36%)
POLY-3 RATE (b)	5/42.70	13/45.25	8/46.26	18/30.23
POLY-3 PERCENT (g)	11.7%	28.7%	17.3%	59.5%
TERMINAL (d)	2/32 (6%)	7/34 (21%)	6/37 (16%)	0/0 (0%)
FIRST INCIDENCE	680	575	598	535
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.041*	P=0.329	P<0.001**
POLY 1.5	P<0.001**	P=0.039*	P=0.315	P<0.001**
POLY 6	P<0.001**	P=0.046*	P=0.345	P<0.001**
COCH-ARM / FISHERS	P=0.008**	P=0.033*	P=0.290	P=0.002**
MAX-ISO-POLY-3	P<0.001**	P=0.025*	P=0.237	P<0.001**

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Esophagus				
Inflammation Acute				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/49 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	1/46.67	0/19.23
POLY-3 PERCENT (g)	0%	0%	2.1%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	3	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Esophagus				
Necrosis				
<hr/>				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	1/43.38	0/44.47	0/45.67	0/19.23
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	698	---	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Esophagus: Muscularis Degeneration

LESION RATES

OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	3/49 (6%)
POLY-3 RATE (b)	1/43.76	1/44.47	2/45.67	3/21.00
POLY-3 PERCENT (g)	2.3%	2.3%	4.4%	14.3%
TERMINAL (d)	0/33 (0%)	1/35 (3%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	579	729 (T)	729 (T)	542

STATISTICAL TESTS

POLY 3	P=0.053	P=0.757N	P=0.515	P=0.117
POLY 1.5	P=0.091	P=0.756N	P=0.510	P=0.190
POLY 6	P=0.067	P=0.758N	P=0.521	P=0.059
COCH-ARM / FISHERS	P=0.174	P=0.753N	P=0.500	P=0.301
MAX-ISO-POLY-3	P=0.087	P=0.495N	P=0.297	P=0.093

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Harderian Gland Hyperplasia				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/49 (4%)	2/50 (4%)	1/49 (2%)
POLY-3 RATE (b)	1/43.60	2/43.47	2/45.81	1/19.82
POLY-3 PERCENT (g)	2.3%	4.6%	4.4%	5.1%
TERMINAL (d)	0/33 (0%)	2/34 (6%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	632	729 (T)	695	542
STATISTICAL TESTS				
POLY 3	P=0.462	P=0.499	P=0.517	P=0.567
POLY 1.5	P=0.602	P=0.500	P=0.511	P=0.666
POLY 6	P=0.426	P=0.498	P=0.524	P=0.425
COCH-ARM / FISHERS	P=0.511N	P=0.492	P=0.500	P=0.747
MAX-ISO-POLY-3	P=0.588	P=0.280	P=0.299	P=0.347

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Heart				
Cardiomyopathy				
LESION RATES				
OVERALL (a)	4/50 (8%)	8/50 (16%)	5/50 (10%)	0/49 (0%)
POLY-3 RATE (b)	4/44.15	8/45.33	5/46.12	0/19.23
POLY-3 PERCENT (g)	9.1%	17.7%	10.8%	0%
TERMINAL (d)	3/33 (9%)	6/35 (17%)	4/37 (11%)	0/0 (0%)
FIRST INCIDENCE	340	590	598	---
STATISTICAL TESTS				
POLY 3	P=0.142N	P=0.189	P=0.527	P=0.244N
POLY 1.5	P=0.055N	P=0.187	P=0.516	P=0.133N
POLY 6	P=0.342N	P=0.195	P=0.544	P=0.456N
COCH-ARM / FISHERS	P=0.013N*	P=0.178	P=0.500	P=0.061N
MAX-ISO-POLY-3	P=0.233N	P=0.119	P=0.390	P=0.182N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Heart Mineralization				
LESION RATES				
OVERALL (a)	1/50 (2%)	4/50 (8%)	2/50 (4%)	1/49 (2%)
POLY-3 RATE (b)	1/43.26	4/45.93	2/45.89	1/19.82
POLY-3 PERCENT (g)	2.3%	8.7%	4.4%	5.1%
TERMINAL (d)	1/33 (3%)	1/35 (3%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	522	677	542
STATISTICAL TESTS				
POLY 3	P=0.532N	P=0.197	P=0.521	P=0.569
POLY 1.5	P=0.437N	P=0.192	P=0.513	P=0.668
POLY 6	P=0.627	P=0.205	P=0.530	P=0.427
COCH-ARM / FISHERS	P=0.306N	P=0.181	P=0.500	P=0.747
MAX-ISO-POLY-3	P=0.544	P=0.101	P=0.303	P=0.347

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Islets, Pancreatic Hyperplasia				
LESION RATES				
OVERALL (a)	3/50 (6%)	3/48 (6%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/43.43	3/43.99	2/45.67	1/20.25
POLY-3 PERCENT (g)	6.9%	6.8%	4.4%	4.9%
TERMINAL (d)	2/33 (6%)	1/35 (3%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	684	568	729 (T)	515
STATISTICAL TESTS				
POLY 3	P=0.407N	P=0.657N	P=0.477N	P=0.587N
POLY 1.5	P=0.323N	P=0.662	P=0.485N	P=0.445N
POLY 6	P=0.498N	P=0.648N	P=0.468N	P=0.571
COCH-ARM / FISHERS	P=0.204N	P=0.641	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.632N	P=0.493N	P=0.308N	P=0.417N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Kidney Infarct				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/49 (2%)	1/48 (2%)
POLY-3 RATE (b)	0/43.26	0/44.47	1/45.28	1/19.69
POLY-3 PERCENT (g)	0%	0%	2.2%	5.1%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	542
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney				
Infiltration Cellular Mononuclear Cell				
LESION RATES				
OVERALL (a)	38/50 (76%)	44/50 (88%)	43/49 (88%)	45/48 (94%)
POLY-3 RATE (b)	38/46.09	44/48.54	43/47.67	45/46.14
POLY-3 PERCENT (g)	82.4%	90.7%	90.2%	97.5%
TERMINAL (d)	29/33 (88%)	32/35 (91%)	34/37 (92%)	0/0 (0%)
FIRST INCIDENCE	438	421	563	432
STATISTICAL TESTS				
POLY 3	P=0.023*	P=0.175	P=0.201	P=0.009**
POLY 1.5	P=0.030*	P=0.157	P=0.150	P=0.013*
POLY 6	P=0.019*	P=0.209	P=0.279	P=0.008**
COCH-ARM / FISHERS	P=0.036*	P=0.096	P=0.104	P=0.014*
MAX-ISO-POLY-3	P=0.008**	P=0.109	P=0.129	P=0.003**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney				
Metaplasia Osseous				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/49 (2%)	1/48 (2%)
POLY-3 RATE (b)	0/43.26	0/44.47	1/45.82	1/19.69
POLY-3 PERCENT (g)	0%	0%	2.2%	5.1%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	563	542
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney Mineralization				
LESION RATES				
OVERALL (a)	7/50 (14%)	5/50 (10%)	5/49 (10%)	1/48 (2%)
POLY-3 RATE (b)	7/44.50	5/44.53	5/45.61	1/19.69
POLY-3 PERCENT (g)	15.7%	11.2%	11%	5.1%
TERMINAL (d)	3/33 (9%)	4/35 (11%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	601	715	677	542
STATISTICAL TESTS				
POLY 3	P=0.228N	P=0.378N	P=0.362N	P=0.247N
POLY 1.5	P=0.119N	P=0.371N	P=0.372N	P=0.104N
POLY 6	P=0.394N	P=0.388N	P=0.352N	P=0.543N
COCH-ARM / FISHERS	P=0.038N*	P=0.380N	P=0.394N	P=0.034N*
MAX-ISO-POLY-3	P=0.369N	P=0.268N	P=0.258N	P=0.209N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney Nephropathy				
LESION RATES				
OVERALL (a)	14/50 (28%)	9/50 (18%)	9/49 (18%)	3/48 (6%)
POLY-3 RATE (b)	14/44.43	9/44.53	9/45.44	3/20.87
POLY-3 PERCENT (g)	31.5%	20.2%	19.8%	14.4%
TERMINAL (d)	12/33 (36%)	8/35 (23%)	8/37 (22%)	0/0 (0%)
FIRST INCIDENCE	340	715	688	542
STATISTICAL TESTS				
POLY 3	P=0.152N	P=0.163N	P=0.150N	P=0.142N
POLY 1.5	P=0.055N	P=0.162N	P=0.164N	P=0.030N*
POLY 6	P=0.303N	P=0.161N	P=0.133N	P=0.537N
COCH-ARM / FISHERS	P=0.009N**	P=0.171N	P=0.185N	P=0.004N**
MAX-ISO-POLY-3	P=0.251N	P=0.110N	P=0.104N	P=0.145N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Interstitium Inflammation Chronic				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/49 (0%)	2/48 (4%)
POLY-3 RATE (b)	1/43.43	0/44.47	0/45.28	2/20.28
POLY-3 PERCENT (g)	2.3%	0%	0%	9.9%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	683	---	---	542
STATISTICAL TESTS				
POLY 3	P=0.116	P=0.495N	P=0.492N	P=0.270
POLY 1.5	P=0.123	P=0.495N	P=0.496N	P=0.370
POLY 6	P=0.309	P=0.495N	P=0.487N	P=0.166
COCH-ARM / FISHERS	P=0.164	P=0.500N	P=0.505N	P=0.485
MAX-ISO-POLY-3	P=0.099	P=0.158N	P=0.160N	P=0.179

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

**Kidney: Papilla
Inflammation Acute**

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.28	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Papilla Necrosis				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/43.26	2/44.47	0/45.28	0/19.10
POLY-3 PERCENT (g)	0%	4.5%	0%	0%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.327N	P=0.243	(e)	(e)
POLY 1.5	P=0.343N	P=0.243	(e)	(e)
POLY 6	P=0.389N	P=0.244	(e)	(e)
COCH-ARM / FISHERS	P=0.334N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.522N	P=0.082	(e)	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Renal Tubule Accumulation, Hyaline Droplet				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/49 (0%)	1/48 (2%)
POLY-3 RATE (b)	2/43.99	1/44.77	0/45.28	1/19.85
POLY-3 PERCENT (g)	4.6%	2.2%	0%	5%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	593	647	---	459
STATISTICAL TESTS				
POLY 3	P=0.539N	P=0.494N	P=0.231N	P=0.684
POLY 1.5	P=0.572N	P=0.493N	P=0.235N	P=0.634N
POLY 6	P=0.464N	P=0.494N	P=0.227N	P=0.506
COCH-ARM / FISHERS	P=0.538N	P=0.500N	P=0.253N	P=0.515N
MAX-ISO-POLY-3	P=0.529N	P=0.277N	P=0.077N	P=0.476

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Kidney: Renal Tubule
Cyst

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	1/48 (2%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.28	1/19.69
POLY-3 PERCENT (g)	0%	0%	0%	5.1%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	542

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Renal Tubule Degeneration				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/49 (2%)	0/48 (0%)
POLY-3 RATE (b)	0/43.26	1/45.10	1/45.79	0/19.10
POLY-3 PERCENT (g)	0%	2.2%	2.2%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	522	575	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Renal Tubule Dilatation				
LESION RATES				
OVERALL (a)	31/50 (62%)	23/50 (46%)	34/49 (69%)	43/48 (90%)
POLY-3 RATE (b)	31/46.37	23/47.42	34/47.53	43/45.06
POLY-3 PERCENT (g)	66.9%	48.5%	71.5%	95.4%
TERMINAL (d)	22/33 (67%)	15/35 (43%)	25/37 (68%)	0/0 (0%)
FIRST INCIDENCE	438	473	563	432
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.052N	P=0.394	P<0.001**
POLY 1.5	P<0.001**	P=0.055N	P=0.351	P<0.001**
POLY 6	P<0.001**	P=0.047N*	P=0.446	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.080N	P=0.287	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.034N*	P=0.313	P<0.001**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Kidney: Renal Tubule Pigmentation				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.28	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Basophilic Focus				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/49 (2%)	1/50 (2%)	2/49 (4%)
POLY-3 RATE (b)	1/43.60	1/43.68	1/45.67	2/20.86
POLY-3 PERCENT (g)	2.3%	2.3%	2.2%	9.6%
TERMINAL (d)	0/33 (0%)	1/35 (3%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	632	729 (T)	729 (T)	432
STATISTICAL TESTS				
POLY 3	P=0.190	P=0.760N	P=0.750N	P=0.276
POLY 1.5	P=0.250	P=0.760N	P=0.754N	P=0.377
POLY 6	P=0.273	P=0.760N	P=0.746N	P=0.170
COCH-ARM / FISHERS	P=0.356	P=0.747	P=0.753N	P=0.492
MAX-ISO-POLY-3	P=0.267	P=0.499N	P=0.486N	P=0.182

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Clear Cell Focus				
LESION RATES				
OVERALL (a)	0/50 (0%)	3/49 (6%)	2/50 (4%)	2/49 (4%)
POLY-3 RATE (b)	0/43.26	3/44.02	2/45.67	2/20.65
POLY-3 PERCENT (g)	0%	6.8%	4.4%	9.7%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	---	634	729 (T)	542
STATISTICAL TESTS				
POLY 3	P=0.224	P=0.122	P=0.249	P=0.120
POLY 1.5	P=0.332	P=0.121	P=0.245	P=0.166
POLY 6	P=0.229	P=0.124	P=0.255	P=0.079
COCH-ARM / FISHERS	P=0.490	P=0.117	P=0.247	P=0.242
MAX-ISO-POLY-3	P=0.223	P=0.041*	P=0.088	P=0.071

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Eosinophilic Focus				
LESION RATES				
OVERALL (a)	3/50 (6%)	2/49 (4%)	16/50 (32%)	15/49 (31%)
POLY-3 RATE (b)	3/43.88	2/43.68	16/46.12	15/28.38
POLY-3 PERCENT (g)	6.8%	4.6%	34.7%	52.9%
TERMINAL (d)	1/33 (3%)	2/35 (6%)	15/37 (41%)	0/0 (0%)
FIRST INCIDENCE	579	729 (T)	598	515
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.502N	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.501N	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.503N	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.510N	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.326N	P<0.001**	P<0.001**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Fatty Change				
LESION RATES				
OVERALL (a)	18/50 (36%)	18/49 (37%)	39/50 (78%)	20/49 (41%)
POLY-3 RATE (b)	18/46.69	18/45.89	39/48.56	20/31.25
POLY-3 PERCENT (g)	38.6%	39.2%	80.3%	64%
TERMINAL (d)	11/33 (33%)	13/35 (37%)	30/37 (81%)	0/0 (0%)
FIRST INCIDENCE	340	421	535	542
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.559	P<0.001**	P=0.021*
POLY 1.5	P=0.042*	P=0.567	P<0.001**	P=0.117
POLY 6	P<0.001**	P=0.552	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.433	P=0.553	P<0.001**	P=0.387
MAX-ISO-POLY-3	P=0.002**	P=0.472	P<0.001**	P=0.026*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Hematopoietic Cell Proliferation				
LESION RATES				
OVERALL (a)	13/50 (26%)	15/49 (31%)	8/50 (16%)	13/49 (27%)
POLY-3 RATE (b)	13/44.34	15/45.08	8/46.86	13/27.35
POLY-3 PERCENT (g)	29.3%	33.3%	17.1%	47.5%
TERMINAL (d)	10/33 (30%)	11/35 (31%)	5/37 (14%)	0/0 (0%)
FIRST INCIDENCE	438	575	563	432
STATISTICAL TESTS				
POLY 3	P=0.197	P=0.431	P=0.126N	P=0.097
POLY 1.5	P=0.348	P=0.421	P=0.140N	P=0.287
POLY 6	P=0.122	P=0.453	P=0.110N	P=0.010**
COCH-ARM / FISHERS	P=0.500N	P=0.387	P=0.163N	P=0.567
MAX-ISO-POLY-3	P=0.123	P=0.345	P=0.087N	P=0.098

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver Hemorrhage				
LESION RATES				
OVERALL (a)	4/50 (8%)	1/49 (2%)	4/50 (8%)	5/49 (10%)
POLY-3 RATE (b)	4/43.26	1/43.68	4/45.67	5/22.42
POLY-3 PERCENT (g)	9.3%	2.3%	8.8%	22.3%
TERMINAL (d)	4/33 (12%)	1/35 (3%)	4/37 (11%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	542
STATISTICAL TESTS				
POLY 3	P=0.041*	P=0.175N	P=0.613N	P=0.160
POLY 1.5	P=0.084	P=0.177N	P=0.624N	P=0.301
POLY 6	P=0.034*	P=0.172N	P=0.600N	P=0.051
COCH-ARM / FISHERS	P=0.194	P=0.187N	P=0.643N	P=0.487
MAX-ISO-POLY-3	P=0.067	P=0.083N	P=0.468N	P=0.142

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	32/50 (64%)	33/49 (67%)	34/50 (68%)	32/49 (65%)
POLY-3 RATE (b)	32/44.82	33/45.82	34/46.86	32/38.46
POLY-3 PERCENT (g)	71.4%	72%	72.6%	83.2%
TERMINAL (d)	25/33 (76%)	26/35 (74%)	28/37 (76%)	0/0 (0%)
FIRST INCIDENCE	589	473	598	515
STATISTICAL TESTS				
POLY 3	P=0.106	P=0.569	P=0.545	P=0.126
POLY 1.5	P=0.284	P=0.544	P=0.497	P=0.319
POLY 6	P=0.021*	P=0.600N	P=0.595	P=0.019*
COCH-ARM / FISHERS	P=0.533N	P=0.445	P=0.417	P=0.530
MAX-ISO-POLY-3	P=0.175	P=0.472	P=0.449	P=0.089

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Mixed Cell Focus				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/49 (4%)	0/50 (0%)	1/49 (2%)
POLY-3 RATE (b)	0/43.26	2/43.68	0/45.67	1/20.06
POLY-3 PERCENT (g)	0%	4.6%	0%	5%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	---	542
STATISTICAL TESTS				
POLY 3	P=0.545	P=0.239	(e)	P=0.364
POLY 1.5	P=0.583	P=0.239	(e)	P=0.427
POLY 6	P=0.678N	P=0.241	(e)	P=0.289
COCH-ARM / FISHERS	P=0.659	P=0.242	(e)	P=0.495
MAX-ISO-POLY-3	P=0.334	P=0.079	(e)	P=0.155

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Necrosis Focal				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/49 (2%)	4/50 (8%)	3/49 (6%)
POLY-3 RATE (b)	1/43.26	1/43.68	4/45.81	3/21.26
POLY-3 PERCENT (g)	2.3%	2.3%	8.7%	14.1%
TERMINAL (d)	1/33 (3%)	1/35 (3%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	695	535
STATISTICAL TESTS				
POLY 3	P=0.037*	P=0.759N	P=0.196	P=0.120
POLY 1.5	P=0.095	P=0.759N	P=0.190	P=0.193
POLY 6	P=0.020*	P=0.757N	P=0.205	P=0.060
COCH-ARM / FISHERS	P=0.221	P=0.747	P=0.181	P=0.301
MAX-ISO-POLY-3	P=0.062	P=0.496N	P=0.100	P=0.094

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver				
Tension Lipidosis				
LESION RATES				
OVERALL (a)	3/50 (6%)	2/49 (4%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	3/43.60	2/43.83	2/45.67	0/19.47
POLY-3 PERCENT (g)	6.9%	4.6%	4.4%	0%
TERMINAL (d)	2/33 (6%)	1/35 (3%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	632	690	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.262N	P=0.498N	P=0.479N	P=0.318N
POLY 1.5	P=0.184N	P=0.498N	P=0.486N	P=0.205N
POLY 6	P=0.426N	P=0.495N	P=0.471N	P=0.508N
COCH-ARM / FISHERS	P=0.105N	P=0.510N	P=0.500N	P=0.125N
MAX-ISO-POLY-3	P=0.379N	P=0.323N	P=0.309N	P=0.213N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Liver: Centrilobular
Necrosis

LESION RATES

OVERALL (a)	0/50 (0%)	0/49 (0%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	0/43.26	0/43.68	2/46.01	0/19.47
POLY-3 PERCENT (g)	0%	0%	4.4%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	677	---

STATISTICAL TESTS

POLY 3	P=0.340	(e)	P=0.251	(e)
POLY 1.5	P=0.577	(e)	P=0.246	(e)
POLY 6	P=0.143	(e)	P=0.258	(e)
COCH-ARM / FISHERS	P=0.695N	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.441	(e)	P=0.090	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver: Hepatocyte, Centrilobular Hypertrophy				
LESION RATES				
OVERALL (a)	0/50 (0%)	7/49 (14%)	45/50 (90%)	47/49 (96%)
POLY-3 RATE (b)	0/43.26	7/43.91	45/48.20	47/47.62
POLY-3 PERCENT (g)	0%	15.9%	93.4%	98.7%
TERMINAL (d)	0/33 (0%)	5/35 (14%)	35/37 (95%)	0/0 (0%)
FIRST INCIDENCE	---	684	563	432
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.008**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.008**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.008**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.006**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.003**	P<0.001**	P<0.001**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Liver: Kupffer Cell Pigmentation				
LESION RATES				
OVERALL (a)	3/50 (6%)	10/49 (20%)	24/50 (48%)	27/49 (55%)
POLY-3 RATE (b)	3/43.39	10/44.49	24/46.35	27/35.67
POLY-3 PERCENT (g)	6.9%	22.5%	51.8%	75.7%
TERMINAL (d)	2/33 (6%)	6/35 (17%)	22/37 (60%)	0/0 (0%)
FIRST INCIDENCE	696	575	563	432
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.037*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.036*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.040*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.033*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.020*	P<0.001**	P<0.001**

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Lung Congestion				
<hr/>				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/43.83	1/44.94	1/45.69	0/19.60
POLY-3 PERCENT (g)	4.6%	2.2%	2.2%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	601	590	726	---
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.331N	P=0.491N	P=0.485N	P=0.437N
POLY 1.5	P=0.279N	P=0.492N	P=0.490N	P=0.331N
POLY 6	P=0.468N	P=0.490N	P=0.481N	P=0.585N
COCH-ARM / FISHERS	P=0.207N	P=0.500N	P=0.500N	P=0.247N
MAX-ISO-POLY-3	P=0.425N	P=0.275N	P=0.272N	P=0.261N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung Hemorrhage				
LESION RATES				
OVERALL (a)	12/50 (24%)	3/50 (6%)	1/50 (2%)	7/50 (14%)
POLY-3 RATE (b)	12/45.16	3/44.68	1/45.67	7/23.78
POLY-3 PERCENT (g)	26.6%	6.7%	2.2%	29.4%
TERMINAL (d)	8/33 (24%)	2/35 (6%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	340	674	729 (T)	515
STATISTICAL TESTS				
POLY 3	P=0.411	P=0.011N*	P<0.001N**	P=0.512
POLY 1.5	P=0.469	P=0.010N**	P<0.001N**	P=0.403N
POLY 6	P=0.552	P=0.011N*	P<0.001N**	P=0.161
COCH-ARM / FISHERS	P=0.520N	P=0.011N*	P<0.001N**	P=0.154N
MAX-ISO-POLY-3	P=0.133	P=0.005N**	P<0.001N**	P=0.423

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung				
Infiltration Cellular Histiocyte				
<hr/>				
LESION RATES				
OVERALL (a)	4/50 (8%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	4/44.50	2/45.39	2/45.67	1/20.25
POLY-3 PERCENT (g)	9%	4.4%	4.4%	4.9%
TERMINAL (d)	2/33 (6%)	0/35 (0%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	340	568	729 (T)	515
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.402N	P=0.328N	P=0.325N	P=0.478N
POLY 1.5	P=0.322N	P=0.329N	P=0.330N	P=0.316N
POLY 6	P=0.487N	P=0.324N	P=0.318N	P=0.611
COCH-ARM / FISHERS	P=0.203N	P=0.339N	P=0.339N	P=0.181N
MAX-ISO-POLY-3	P=0.526N	P=0.196N	P=0.194N	P=0.350N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung				
Inflammation Acute				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	1/46.67	0/19.60
POLY-3 PERCENT (g)	0%	0%	2.1%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	3	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung				
Metaplasia Osseous				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	2/43.39	0/44.47	0/45.67	2/20.78
POLY-3 PERCENT (g)	4.6%	0%	0%	9.6%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	696	---	---	542
STATISTICAL TESTS				
POLY 3	P=0.260	P=0.232N	P=0.226N	P=0.421
POLY 1.5	P=0.272	P=0.232N	P=0.230N	P=0.559
POLY 6	P=0.503	P=0.231N	P=0.221N	P=0.254
COCH-ARM / FISHERS	P=0.344	P=0.247N	P=0.247N	P=0.691N
MAX-ISO-POLY-3	P=0.184	P=0.076N	P=0.076N	P=0.296

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung Mineralization				
LESION RATES				
OVERALL (a)	3/50 (6%)	2/50 (4%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	3/43.26	2/44.47	3/45.87	0/19.60
POLY-3 PERCENT (g)	6.9%	4.5%	6.5%	0%
TERMINAL (d)	3/33 (9%)	2/35 (6%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	677	---
STATISTICAL TESTS				
POLY 3	P=0.352N	P=0.487N	P=0.635N	P=0.314N
POLY 1.5	P=0.224N	P=0.488N	P=0.645N	P=0.201N
POLY 6	P=0.604N	P=0.485N	P=0.622N	P=0.505N
COCH-ARM / FISHERS	P=0.113N	P=0.500N	P=0.661N	P=0.121N
MAX-ISO-POLY-3	P=0.397N	P=0.315N	P=0.470N	P=0.210N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung Thrombosis				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.43	0/44.47	1/45.67	1/20.19
POLY-3 PERCENT (g)	2.3%	0%	2.2%	5%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	684	---	729 (T)	542
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lung: Alveolar Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	1/45.67	0/19.60
POLY-3 PERCENT (g)	0%	0%	2.2%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node Ectasia				
LESION RATES				
OVERALL (a)	3/9 (33%)	6/17 (35%)	4/12 (33%)	0/4 (0%)
POLY-3 RATE (b)	3/8.15	6/15.67	4/11.34	0/1.37
POLY-3 PERCENT (g)	36.8%	38.3%	35.3%	0%
TERMINAL (d)	3/6 (50%)	6/15 (40%)	2/8 (25%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	563	---
STATISTICAL TESTS				
POLY 3	P=0.434N	P=0.642	P=0.653N	P=0.537N
POLY 1.5	P=0.317N	P=0.630	P=0.663N	P=0.419N
POLY 6	P=0.556N	P=0.666N	P=0.634N	P=0.665N
COCH-ARM / FISHERS	P=0.184N	P=0.635	P=0.676N	P=0.294N
MAX-ISO-POLY-3	P=0.547N	P=0.475	P=0.474N	P=0.331N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node Hemorrhage				
LESION RATES				
OVERALL (a)	3/9 (33%)	5/17 (29%)	3/12 (25%)	0/4 (0%)
POLY-3 RATE (b)	3/8.15	5/15.67	3/11.34	0/1.37
POLY-3 PERCENT (g)	36.8%	31.9%	26.5%	0%
TERMINAL (d)	3/6 (50%)	5/15 (33%)	1/8 (13%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	563	---
STATISTICAL TESTS				
POLY 3	P=0.360N	P=0.583N	P=0.503N	P=0.537N
POLY 1.5	P=0.283N	P=0.592N	P=0.515N	P=0.419N
POLY 6	P=0.447N	P=0.556N	P=0.483N	P=0.665N
COCH-ARM / FISHERS	P=0.190N	P=0.587N	P=0.523N	P=0.294N
MAX-ISO-POLY-3	P=0.544N	P=0.418N	P=0.332N	P=0.331N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node				
Hyperplasia Lymphoid				
LESION RATES				
OVERALL (a)	0/9 (0%)	2/17 (12%)	0/12 (0%)	1/4 (25%)
POLY-3 RATE (b)	0/8.15	2/16.47	0/10.66	1/1.98
POLY-3 PERCENT (g)	0%	12.1%	0%	50.6%
TERMINAL (d)	0/6 (0%)	1/15 (7%)	0/8 (0%)	0/0 (0%)
FIRST INCIDENCE	---	421	---	535
STATISTICAL TESTS				
POLY 3	P=0.359	P=0.403	(e)	P=0.233
POLY 1.5	P=0.363	P=0.394	(e)	P=0.270
POLY 6	P=0.455	P=0.417	(e)	P=0.200
COCH-ARM / FISHERS	P=0.394	P=0.418	(e)	P=0.308
MAX-ISO-POLY-3	P=0.134	P=0.195	(e)	P=0.073

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node Pigmentation				
LESION RATES				
OVERALL (a)	3/9 (33%)	5/17 (29%)	5/12 (42%)	0/4 (0%)
POLY-3 RATE (b)	3/8.15	5/15.67	5/10.80	0/1.37
POLY-3 PERCENT (g)	36.8%	31.9%	46.3%	0%
TERMINAL (d)	3/6 (50%)	5/15 (33%)	4/8 (50%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	695	---
STATISTICAL TESTS				
POLY 3	P=0.542	P=0.583N	P=0.522	P=0.537N
POLY 1.5	P=0.493N	P=0.592N	P=0.521	P=0.419N
POLY 6	P=0.384	P=0.556N	P=0.530	P=0.665N
COCH-ARM / FISHERS	P=0.278N	P=0.587N	P=0.528	P=0.294N
MAX-ISO-POLY-3	P=0.545N	P=0.418N	P=0.351	P=0.331N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mandibular Hemorrhage				
LESION RATES				
OVERALL (a)	0/48 (0%)	0/50 (0%)	0/50 (0%)	1/45 (2%)
POLY-3 RATE (b)	0/42.28	0/44.47	0/45.67	1/18.56
POLY-3 PERCENT (g)	0%	0%	0%	5.4%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	542
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mandibular Hyperplasia Lymphoid				
LESION RATES				
OVERALL (a)	3/48 (6%)	3/50 (6%)	2/50 (4%)	0/45 (0%)
POLY-3 RATE (b)	3/42.63	3/44.47	2/46.12	0/17.97
POLY-3 PERCENT (g)	7%	6.8%	4.3%	0%
TERMINAL (d)	2/33 (6%)	3/35 (9%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	632	729 (T)	598	---
STATISTICAL TESTS				
POLY 3	P=0.212N	P=0.643N	P=0.464N	P=0.333N
POLY 1.5	P=0.150N	P=0.640N	P=0.471N	P=0.218N
POLY 6	P=0.331N	P=0.645N	P=0.455N	P=0.517N
COCH-ARM / FISHERS	P=0.083N	P=0.641N	P=0.480N	P=0.133N
MAX-ISO-POLY-3	P=0.348N	P=0.478N	P=0.298N	P=0.224N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mandibular Pigmentation				
LESION RATES				
OVERALL (a)	36/48 (75%)	39/50 (78%)	41/50 (82%)	38/45 (84%)
POLY-3 RATE (b)	36/45.97	39/47.45	41/48.24	38/40.42
POLY-3 PERCENT (g)	78.3%	82.2%	85%	94%
TERMINAL (d)	26/33 (79%)	30/35 (86%)	31/37 (84%)	0/0 (0%)
FIRST INCIDENCE	438	473	563	515
STATISTICAL TESTS				
POLY 3	P=0.026*	P=0.414	P=0.280	P=0.025*
POLY 1.5	P=0.067	P=0.458	P=0.273	P=0.077
POLY 6	P=0.010**	P=0.372	P=0.302	P=0.007**
COCH-ARM / FISHERS	P=0.176	P=0.455	P=0.275	P=0.192
MAX-ISO-POLY-3	P=0.035*	P=0.315	P=0.200	P=0.014*

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Atrophy				
LESION RATES				
OVERALL (a)	1/48 (2%)	0/45 (0%)	1/49 (2%)	1/48 (2%)
POLY-3 RATE (b)	1/42.15	0/39.98	1/44.89	1/19.69
POLY-3 PERCENT (g)	2.4%	0%	2.2%	5.1%
TERMINAL (d)	0/31 (0%)	0/32 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	340	---	677	542
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Lymph Node, Mesenteric
Congestion

LESION RATES

OVERALL (a)	0/48 (0%)	0/45 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/41.26	0/39.98	0/44.69	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/32 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Ectasia				
LESION RATES				
OVERALL (a)	0/48 (0%)	1/45 (2%)	3/49 (6%)	0/48 (0%)
POLY-3 RATE (b)	0/41.26	1/39.98	3/44.69	0/19.10
POLY-3 PERCENT (g)	0%	2.5%	6.7%	0%
TERMINAL (d)	0/31 (0%)	1/32 (3%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.408	P=0.494	P=0.133	(e)
POLY 1.5	P=0.641N	P=0.493	P=0.129	(e)
POLY 6	P=0.162	P=0.496	P=0.138	(e)
COCH-ARM / FISHERS	P=0.466N	P=0.484	P=0.125	(e)
MAX-ISO-POLY-3	P=0.422	P=0.154	P=0.050*	(e)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Hemorrhage				
LESION RATES				
OVERALL (a)	0/48 (0%)	2/45 (4%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/41.26	2/39.98	0/44.69	0/19.10
POLY-3 PERCENT (g)	0%	5%	0%	0%
TERMINAL (d)	0/31 (0%)	2/32 (6%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
STATISTICAL TESTS				
POLY 3	P=0.313N	P=0.230	(e)	(e)
POLY 1.5	P=0.330N	P=0.229	(e)	(e)
POLY 6	P=0.372N	P=0.232	(e)	(e)
COCH-ARM / FISHERS	P=0.321N	P=0.231	(e)	(e)
MAX-ISO-POLY-3	P=0.501N	P=0.072	(e)	(e)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Necrosis Lymphoid				
LESION RATES				
OVERALL (a)	0/48 (0%)	0/45 (0%)	0/49 (0%)	2/48 (4%)
POLY-3 RATE (b)	0/41.26	0/39.98	0/44.69	2/20.28
POLY-3 PERCENT (g)	0%	0%	0%	9.9%
TERMINAL (d)	0/31 (0%)	0/32 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	542
STATISTICAL TESTS				
POLY 3	P=0.025*	(e)	(e)	P=0.123
POLY 1.5	P=0.028*	(e)	(e)	P=0.171
POLY 6	P=0.113	(e)	(e)	P=0.081
COCH-ARM / FISHERS	P=0.043*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.035*	(e)	(e)	P=0.072

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Lymph Node, Mesenteric Pigmentation				
LESION RATES				
OVERALL (a)	0/48 (0%)	0/45 (0%)	0/49 (0%)	2/48 (4%)
POLY-3 RATE (b)	0/41.26	0/39.98	0/44.69	2/20.28
POLY-3 PERCENT (g)	0%	0%	0%	9.9%
TERMINAL (d)	0/31 (0%)	0/32 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	542
STATISTICAL TESTS				
POLY 3	P=0.025*	(e)	(e)	P=0.123
POLY 1.5	P=0.028*	(e)	(e)	P=0.171
POLY 6	P=0.113	(e)	(e)	P=0.081
COCH-ARM / FISHERS	P=0.043*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.035*	(e)	(e)	P=0.072

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Mammary Gland Galactocele				
LESION RATES				
OVERALL (a)	30/50 (60%)	28/50 (56%)	32/50 (64%)	31/50 (62%)
POLY-3 RATE (b)	30/46.56	28/47.01	32/47.01	31/38.01
POLY-3 PERCENT (g)	64.4%	59.6%	68.1%	81.6%
TERMINAL (d)	20/33 (61%)	18/35 (51%)	25/37 (68%)	0/0 (0%)
FIRST INCIDENCE	579	575	563	515
STATISTICAL TESTS				
POLY 3	P=0.022*	P=0.392N	P=0.438	P=0.051
POLY 1.5	P=0.104	P=0.381N	P=0.440	P=0.210
POLY 6	P=0.002**	P=0.399N	P=0.425	P=0.004**
COCH-ARM / FISHERS	P=0.379	P=0.420N	P=0.418	P=0.500
MAX-ISO-POLY-3	P=0.036*	P=0.313N	P=0.353	P=0.041*

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Mammary Gland Hyperplasia				
LESION RATES				
OVERALL (a)	3/50 (6%)	0/50 (0%)	5/50 (10%)	0/50 (0%)
POLY-3 RATE (b)	3/43.26	0/44.47	5/45.67	0/19.60
POLY-3 PERCENT (g)	6.9%	0%	11%	0%
TERMINAL (d)	3/33 (9%)	0/35 (0%)	5/37 (14%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---
STATISTICAL TESTS				
POLY 3	P=0.473	P=0.114N	P=0.387	P=0.314N
POLY 1.5	P=0.456N	P=0.114N	P=0.376	P=0.201N
POLY 6	P=0.163	P=0.112N	P=0.400	P=0.505N
COCH-ARM / FISHERS	P=0.234N	P=0.121N	P=0.357	P=0.121N
MAX-ISO-POLY-3	P=0.392N	P=0.038N*	P=0.261	P=0.210N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Mammary Gland Inflammation Chronic				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	1/43.26	2/44.47	4/45.67	2/21.08
POLY-3 PERCENT (g)	2.3%	4.5%	8.8%	9.5%
TERMINAL (d)	1/33 (3%)	2/35 (6%)	4/37 (11%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	366
STATISTICAL TESTS				
POLY 3	P=0.159	P=0.510	P=0.195	P=0.281
POLY 1.5	P=0.311	P=0.509	P=0.189	P=0.383
POLY 6	P=0.085	P=0.512	P=0.203	P=0.172
COCH-ARM / FISHERS	P=0.528	P=0.500	P=0.181	P=0.500
MAX-ISO-POLY-3	P=0.261	P=0.291	P=0.099	P=0.185

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Mesentery: Artery
Inflammation Chronic

LESION RATES

OVERALL (a)	0/11 (0%)	0/26 (0%)	0/12 (0%)	0/5 (0%)
POLY-3 RATE (b)	0/10.21	0/23.48	0/10.89	0/1.77
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/20 (0%)	0/10 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Mesentery: Fat
Necrosis

LESION RATES

OVERALL (a)	10/11 (91%)	22/26 (85%)	12/12 (100%)	3/5 (60%)
POLY-3 RATE (b)	10/10.53	22/24.96	12/12.00	3/3.57
POLY-3 PERCENT (g)	95%	88.1%	100%	84.2%
TERMINAL (d)	8/8 (100%)	18/20 (90%)	10/10 (100%)	0/0 (0%)
FIRST INCIDENCE	680	522	535	535

STATISTICAL TESTS

POLY 3	P=0.689	P=0.496N	P=0.793	P=0.741N
POLY 1.5	P=0.539N	P=0.502N	P=0.625	P=0.442N
POLY 6	P=0.501	P=0.480N	P=0.993	P=0.998N
COCH-ARM / FISHERS	P=0.218N	P=0.528N	P=0.478	P=0.214N
MAX-ISO-POLY-3	P=0.478N	P=0.283N	P=0.158	P=0.243N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Nose				
Foreign Body				
LESION RATES				
OVERALL (a)	4/50 (8%)	3/50 (6%)	3/50 (6%)	3/48 (6%)
POLY-3 RATE (b)	4/43.26	3/44.94	3/45.67	3/20.87
POLY-3 PERCENT (g)	9.3%	6.7%	6.6%	14.4%
TERMINAL (d)	4/33 (12%)	2/35 (6%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	590	729 (T)	542
STATISTICAL TESTS				
POLY 3	P=0.353	P=0.479N	P=0.470N	P=0.433
POLY 1.5	P=0.481	P=0.483N	P=0.481N	P=0.609
POLY 6	P=0.362	P=0.473N	P=0.457N	P=0.218
COCH-ARM / FISHERS	P=0.530N	P=0.500N	P=0.500N	P=0.523N
MAX-ISO-POLY-3	P=0.445	P=0.331N	P=0.325N	P=0.331

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Nose				
Fungus				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.67	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Nose				
Inflammation Acute				
LESION RATES				
OVERALL (a)	6/50 (12%)	6/50 (12%)	4/50 (8%)	10/48 (21%)
POLY-3 RATE (b)	6/43.55	6/45.60	4/45.67	10/25.19
POLY-3 PERCENT (g)	13.8%	13.2%	8.8%	39.7%
TERMINAL (d)	4/33 (12%)	3/35 (9%)	4/37 (11%)	0/0 (0%)
FIRST INCIDENCE	684	421	729 (T)	496
STATISTICAL TESTS				
POLY 3	P=0.014*	P=0.588N	P=0.340N	P=0.017*
POLY 1.5	P=0.031*	P=0.594N	P=0.350N	P=0.064
POLY 6	P=0.011*	P=0.581N	P=0.329N	P=0.002**
COCH-ARM / FISHERS	P=0.089	P=0.620N	P=0.370N	P=0.182
MAX-ISO-POLY-3	P=0.022*	P=0.466N	P=0.233N	P=0.024*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Nose				
Mineralization				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/48 (2%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.67	1/19.69
POLY-3 PERCENT (g)	0%	0%	0%	5.1%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	542
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Ovary Cyst				
LESION RATES				
OVERALL (a)	13/48 (27%)	13/49 (27%)	6/50 (12%)	7/48 (15%)
POLY-3 RATE (b)	13/42.00	13/44.56	6/45.83	7/23.28
POLY-3 PERCENT (g)	31%	29.2%	13.1%	30.1%
TERMINAL (d)	8/31 (26%)	8/34 (24%)	5/37 (14%)	0/0 (0%)
FIRST INCIDENCE	680	575	688	515
STATISTICAL TESTS				
POLY 3	P=0.303N	P=0.522N	P=0.036N*	P=0.577N
POLY 1.5	P=0.187N	P=0.529N	P=0.040N*	P=0.290N
POLY 6	P=0.359N	P=0.511N	P=0.032N*	P=0.226
COCH-ARM / FISHERS	P=0.067N	P=0.566N	P=0.051N	P=0.104N
MAX-ISO-POLY-3	P=0.366N	P=0.428N	P=0.023N*	P=0.476N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas Atrophy				
LESION RATES				
OVERALL (a)	6/50 (12%)	8/48 (17%)	5/50 (10%)	0/50 (0%)
POLY-3 RATE (b)	6/43.90	8/43.76	5/46.18	0/19.60
POLY-3 PERCENT (g)	13.7%	18.3%	10.8%	0%
TERMINAL (d)	4/33 (12%)	6/35 (17%)	4/37 (11%)	0/0 (0%)
FIRST INCIDENCE	589	618	575	---
STATISTICAL TESTS				
POLY 3	P=0.075N	P=0.383	P=0.465N	P=0.136N
POLY 1.5	P=0.026N*	P=0.379	P=0.477N	P=0.050N*
POLY 6	P=0.198N	P=0.391	P=0.451N	P=0.371N
COCH-ARM / FISHERS	P=0.005N**	P=0.355	P=0.500N	P=0.013N*
MAX-ISO-POLY-3	P=0.124N	P=0.280	P=0.344N	P=0.122N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas				
Cyst				
<hr/>				
LESION RATES				
OVERALL (a)	1/50 (2%)	3/48 (6%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.76	3/43.76	3/46.35	0/19.60
POLY-3 PERCENT (g)	2.3%	6.9%	6.5%	0%
TERMINAL (d)	0/33 (0%)	1/35 (3%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	579	618	563	---
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.470N	P=0.305	P=0.326	P=0.639N
POLY 1.5	P=0.307N	P=0.302	P=0.319	P=0.574N
POLY 6	P=0.528	P=0.310	P=0.336	P=0.714N
COCH-ARM / FISHERS	P=0.168N	P=0.293	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.466N	P=0.156	P=0.176	P=0.327N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	29/50 (58%)	32/48 (67%)	31/50 (62%)	22/50 (44%)
POLY-3 RATE (b)	29/45.55	32/45.11	31/46.85	22/32.59
POLY-3 PERCENT (g)	63.7%	70.9%	66.2%	67.5%
TERMINAL (d)	24/33 (73%)	27/35 (77%)	26/37 (70%)	0/0 (0%)
FIRST INCIDENCE	438	473	598	535
STATISTICAL TESTS				
POLY 3	P=0.542	P=0.298	P=0.486	P=0.453
POLY 1.5	P=0.200N	P=0.294	P=0.460	P=0.374N
POLY 6	P=0.149	P=0.314	P=0.527	P=0.075
COCH-ARM / FISHERS	P=0.022N*	P=0.250	P=0.419	P=0.115N
MAX-ISO-POLY-3	P=0.565	P=0.225	P=0.397	P=0.370

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas				
Mineralization				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/48 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	0/43.31	0/45.67	0/19.60
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas Necrosis				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/48 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/43.26	1/43.70	0/45.67	1/20.19
POLY-3 PERCENT (g)	2.3%	2.3%	0%	5%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	618	---	542
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Parathyroid Gland Cyst				
LESION RATES				
OVERALL (a)	2/44 (5%)	1/48 (2%)	1/47 (2%)	0/47 (0%)
POLY-3 RATE (b)	2/39.21	1/42.47	1/43.20	0/18.42
POLY-3 PERCENT (g)	5.1%	2.4%	2.3%	0%
TERMINAL (d)	2/30 (7%)	1/33 (3%)	0/35 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	726	---
STATISTICAL TESTS				
POLY 3	P=0.321N	P=0.472N	P=0.466N	P=0.426N
POLY 1.5	P=0.272N	P=0.471N	P=0.473N	P=0.320N
POLY 6	P=0.448N	P=0.472N	P=0.457N	P=0.577N
COCH-ARM / FISHERS	P=0.202N	P=0.467N	P=0.475N	P=0.231N
MAX-ISO-POLY-3	P=0.411N	P=0.260N	P=0.259N	P=0.254N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Peripheral Nerve Degeneration				
LESION RATES				
OVERALL (a)	1/1 (100%)	0/1 (0%)	1/1 (100%)	0/1 (0%)
POLY-3 RATE (b)	1/1.00	0/0.27	1/1.00	0/0.41
POLY-3 PERCENT (g)	100%	0%	100%	0%
TERMINAL (d)	1/1 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	598	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pituitary Gland: Pars Distalis Cyst				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/47 (0%)	1/46 (2%)	0/45 (0%)
POLY-3 RATE (b)	2/43.26	0/43.13	1/43.42	0/17.90
POLY-3 PERCENT (g)	4.6%	0%	2.3%	0%
TERMINAL (d)	2/33 (6%)	0/35 (0%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	563	---
STATISTICAL TESTS				
POLY 3	P=0.463N	P=0.238N	P=0.499N	P=0.454N
POLY 1.5	P=0.403N	P=0.241N	P=0.511N	P=0.353N
POLY 6	P=0.634N	P=0.233N	P=0.484N	P=0.594N
COCH-ARM / FISHERS	P=0.325N	P=0.263N	P=0.532N	P=0.274N
MAX-ISO-POLY-3	P=0.396N	P=0.079N	P=0.283N	P=0.271N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pituitary Gland: Pars Distalis Hyperplasia				
LESION RATES				
OVERALL (a)	9/50 (18%)	13/47 (28%)	13/46 (28%)	10/45 (22%)
POLY-3 RATE (b)	9/44.10	13/43.62	13/43.02	10/23.79
POLY-3 PERCENT (g)	20.4%	29.8%	30.2%	42%
TERMINAL (d)	6/33 (18%)	11/35 (31%)	12/36 (33%)	0/0 (0%)
FIRST INCIDENCE	587	634	695	542
STATISTICAL TESTS				
POLY 3	P=0.091	P=0.221	P=0.209	P=0.060
POLY 1.5	P=0.254	P=0.213	P=0.194	P=0.180
POLY 6	P=0.025*	P=0.230	P=0.227	P=0.008**
COCH-ARM / FISHERS	P=0.539N	P=0.186	P=0.171	P=0.398
MAX-ISO-POLY-3	P=0.150	P=0.157	P=0.147	P=0.068

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Pituitary Gland: Pars Distalis				
Hyperplasia Focal				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/47 (0%)	0/46 (0%)	0/45 (0%)
POLY-3 RATE (b)	0/43.26	0/43.13	0/42.88	0/17.90
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Salivary Glands Atrophy				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/48 (0%)
POLY-3 RATE (b)	1/43.60	0/44.47	1/45.87	0/18.91
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	632	---	677	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Salivary Glands				
Infiltration Cellular Mononuclear Cell				
LESION RATES				
OVERALL (a)	32/50 (64%)	37/50 (74%)	30/50 (60%)	26/48 (54%)
POLY-3 RATE (b)	32/45.02	37/48.90	30/47.09	26/34.28
POLY-3 PERCENT (g)	71.1%	75.7%	63.7%	75.9%
TERMINAL (d)	26/33 (79%)	26/35 (74%)	25/37 (68%)	0/0 (0%)
FIRST INCIDENCE	579	421	563	535
STATISTICAL TESTS				
POLY 3	P=0.503	P=0.391	P=0.293N	P=0.403
POLY 1.5	P=0.284N	P=0.326	P=0.336N	P=0.480N
POLY 6	P=0.172	P=0.480	P=0.248N	P=0.078
COCH-ARM / FISHERS	P=0.058N	P=0.194	P=0.418N	P=0.216N
MAX-ISO-POLY-3	P=0.498	P=0.310	P=0.225N	P=0.318

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Salivary Glands Mineralization				
LESION RATES				
OVERALL (a)	1/50 (2%)	5/50 (10%)	5/50 (10%)	1/48 (2%)
POLY-3 RATE (b)	1/43.26	5/44.47	5/46.15	1/19.50
POLY-3 PERCENT (g)	2.3%	11.2%	10.8%	5.1%
TERMINAL (d)	1/33 (3%)	5/35 (14%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	656	542
STATISTICAL TESTS				
POLY 3	P=0.483	P=0.107	P=0.117	P=0.565
POLY 1.5	P=0.461N	P=0.107	P=0.111	P=0.663
POLY 6	P=0.279	P=0.108	P=0.125	P=0.425
COCH-ARM / FISHERS	P=0.249N	P=0.102	P=0.102	P=0.742
MAX-ISO-POLY-3	P=0.419	P=0.050*	P=0.058	P=0.345

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skeletal Muscle Fibrosis				
LESION RATES				
OVERALL (a)	0/2 (0%)	0/3 (0%)	1/4 (25%)	0/1 (0%)
POLY-3 RATE (b)	0/1.65	0/1.83	1/2.99	0/0.41
POLY-3 PERCENT (g)	0%	0%	33.4%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	598	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skeletal Muscle Hemorrhage				
LESION RATES				
OVERALL (a)	0/2 (0%)	0/3 (0%)	2/4 (50%)	0/1 (0%)
POLY-3 RATE (b)	0/1.65	0/1.83	2/3.19	0/0.41
POLY-3 PERCENT (g)	0%	0%	62.7%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	598	---
STATISTICAL TESTS				
POLY 3	P=0.364	(e)	P=0.354	(e)
POLY 1.5	P=0.566	(e)	P=0.369	(e)
POLY 6	P=0.168	(e)	P=0.332	(e)
COCH-ARM / FISHERS	P=0.715	(e)	P=0.400	(e)
MAX-ISO-POLY-3	P=0.526	(e)	P=0.109	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skeletal Muscle Inflammation Chronic				
LESION RATES				
OVERALL (a)	0/2 (0%)	0/3 (0%)	1/4 (25%)	0/1 (0%)
POLY-3 RATE (b)	0/1.65	0/1.83	1/2.99	0/0.41
POLY-3 PERCENT (g)	0%	0%	33.4%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	598	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Cyst Epithelial Inclusion				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.28	0/44.47	0/45.67	0/19.60
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	340	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.266N	P=0.236N	P=0.230N	P=0.440N
POLY 1.5	P=0.294N	P=0.235N	P=0.233N	P=0.334N
POLY 6	P=0.291N	P=0.236N	P=0.226N	P=0.586N
COCH-ARM / FISHERS	P=0.289N	P=0.247N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.304N	P=0.076N	P=0.076N	P=0.263N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Edema				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	2/44.47	1/45.83	0/19.60
POLY-3 PERCENT (g)	0%	4.5%	2.2%	0%
TERMINAL (d)	0/33 (0%)	2/35 (6%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	688	---
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.492N	P=0.243	P=0.512	(e)
POLY 1.5	P=0.420N	P=0.243	P=0.507	(e)
POLY 6	P=0.686N	P=0.244	P=0.517	(e)
COCH-ARM / FISHERS	P=0.339N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.526	P=0.082	P=0.173	(e)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Fibrosis				
<hr/>				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.44	0/44.47	2/45.83	0/19.60
POLY-3 PERCENT (g)	2.3%	0%	4.4%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	680	---	688	---
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.534	P=0.495N	P=0.519	P=0.638N
POLY 1.5	P=0.609N	P=0.495N	P=0.512	P=0.573N
POLY 6	P=0.350	P=0.495N	P=0.527	P=0.713N
COCH-ARM / FISHERS	P=0.473N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.561N	P=0.158N	P=0.301	P=0.325N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin Hemorrhage				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.38	2/45.35	0/45.67	0/19.60
POLY-3 PERCENT (g)	2.3%	4.4%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	697	473	---	---
STATISTICAL TESTS				
POLY 3	P=0.213N	P=0.515	P=0.490N	P=0.638N
POLY 1.5	P=0.219N	P=0.512	P=0.493N	P=0.573N
POLY 6	P=0.236N	P=0.519	P=0.486N	P=0.713N
COCH-ARM / FISHERS	P=0.198N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.350N	P=0.297	P=0.158N	P=0.325N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<hr/>				
Skin				
Hyperkeratosis				
<hr/>				
LESION RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.44	1/45.28	0/45.67	0/19.60
POLY-3 PERCENT (g)	2.3%	2.2%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	680	421	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Inflammation Acute				
<hr/>				
LESION RATES				
OVERALL (a)	2/50 (4%)	4/50 (8%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	2/43.62	4/45.70	3/45.97	0/19.60
POLY-3 PERCENT (g)	4.6%	8.8%	6.5%	0%
TERMINAL (d)	0/33 (0%)	1/35 (3%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	680	473	688	---
<hr/>				
STATISTICAL TESTS				
POLY 3	P=0.304N	P=0.359	P=0.524	P=0.436N
POLY 1.5	P=0.181N	P=0.355	P=0.515	P=0.331N
POLY 6	P=0.545N	P=0.364	P=0.534	P=0.585N
COCH-ARM / FISHERS	P=0.085N	P=0.339	P=0.500	P=0.247N
MAX-ISO-POLY-3	P=0.425N	P=0.223	P=0.348	P=0.260N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Inflammation Chronic				
LESION RATES				
OVERALL (a)	8/50 (16%)	10/50 (20%)	13/50 (26%)	10/50 (20%)
POLY-3 RATE (b)	8/43.51	10/44.64	13/46.42	10/25.51
POLY-3 PERCENT (g)	18.4%	22.4%	28%	39.2%
TERMINAL (d)	6/33 (18%)	9/35 (26%)	10/37 (27%)	0/0 (0%)
FIRST INCIDENCE	696	684	598	535
STATISTICAL TESTS				
POLY 3	P=0.051	P=0.420	P=0.203	P=0.058
POLY 1.5	P=0.167	P=0.419	P=0.187	P=0.177
POLY 6	P=0.012*	P=0.422	P=0.224	P=0.007**
COCH-ARM / FISHERS	P=0.462	P=0.398	P=0.163	P=0.398
MAX-ISO-POLY-3	P=0.083	P=0.322	P=0.147	P=0.065

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin Mineralization				
LESION RATES				
OVERALL (a)	0/50 (0%)	2/50 (4%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	0/43.26	2/44.53	2/45.85	1/20.19
POLY-3 PERCENT (g)	0%	4.5%	4.4%	5%
TERMINAL (d)	0/33 (0%)	1/35 (3%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	715	688	542
STATISTICAL TESTS				
POLY 3	P=0.333	P=0.244	P=0.250	P=0.365
POLY 1.5	P=0.482	P=0.243	P=0.245	P=0.429
POLY 6	P=0.280	P=0.245	P=0.257	P=0.290
COCH-ARM / FISHERS	P=0.652N	P=0.247	P=0.247	P=0.500
MAX-ISO-POLY-3	P=0.423	P=0.082	P=0.089	P=0.157

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin				
Ulcer				
LESION RATES				
OVERALL (a)	4/50 (8%)	4/50 (8%)	6/50 (12%)	0/50 (0%)
POLY-3 RATE (b)	4/43.74	4/44.97	6/46.26	0/19.60
POLY-3 PERCENT (g)	9.1%	8.9%	13%	0%
TERMINAL (d)	1/33 (3%)	2/35 (6%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	680	634	688	---
STATISTICAL TESTS				
POLY 3	P=0.372N	P=0.628N	P=0.405	P=0.237N
POLY 1.5	P=0.169N	P=0.629N	P=0.392	P=0.127N
POLY 6	P=0.460	P=0.626N	P=0.421	P=0.453N
COCH-ARM / FISHERS	P=0.050N*	P=0.643N	P=0.370	P=0.059N
MAX-ISO-POLY-3	P=0.345N	P=0.483N	P=0.289	P=0.176N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Skin: Lip
Inflammation Acute

LESION RATES

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.67	0/19.60
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Skin: Lip
Inflammation Chronic

LESION RATES

OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.26	2/44.54	0/45.67	0/19.60
POLY-3 PERCENT (g)	2.3%	4.5%	0%	0%
TERMINAL (d)	1/33 (3%)	1/35 (3%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	712	---	---

STATISTICAL TESTS

POLY 3	P=0.212N	P=0.510	P=0.489N	P=0.638N
POLY 1.5	P=0.219N	P=0.509	P=0.493N	P=0.573N
POLY 6	P=0.232N	P=0.513	P=0.484N	P=0.713N
COCH-ARM / FISHERS	P=0.198N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.348N	P=0.292	P=0.158N	P=0.324N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin: Prepuce				
Inflammation Acute				
<hr/>				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.67	0/19.60
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
<hr/>				
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Skin: Tail, Epidermis
Hyperkeratosis

LESION RATES

OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.43	0/44.47	2/45.99	0/19.60
POLY-3 PERCENT (g)	2.3%	0%	4.4%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	684	---	688	---

STATISTICAL TESTS

POLY 3	P=0.534	P=0.495N	P=0.520	P=0.638N
POLY 1.5	P=0.609N	P=0.495N	P=0.513	P=0.573N
POLY 6	P=0.351	P=0.495N	P=0.529	P=0.713N
COCH-ARM / FISHERS	P=0.473N	P=0.500N	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.561N	P=0.158N	P=0.302	P=0.325N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Skin: Tail, Epidermis Hyperplasia				
LESION RATES				
OVERALL (a)	1/50 (2%)	4/50 (8%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.44	4/44.81	3/45.95	0/19.60
POLY-3 PERCENT (g)	2.3%	8.9%	6.5%	0%
TERMINAL (d)	0/33 (0%)	3/35 (9%)	2/37 (5%)	0/0 (0%)
FIRST INCIDENCE	680	634	656	---
STATISTICAL TESTS				
POLY 3	P=0.386N	P=0.188	P=0.326	P=0.638N
POLY 1.5	P=0.241N	P=0.187	P=0.318	P=0.573N
POLY 6	P=0.616	P=0.190	P=0.334	P=0.713N
COCH-ARM / FISHERS	P=0.124N	P=0.181	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.443N	P=0.092	P=0.175	P=0.325N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spinal Cord Degeneration				
LESION RATES				
OVERALL (a)	0/1 (0%)	0/1 (0%)	2/3 (67%)	0/1 (0%)
POLY-3 RATE (b)	0/1.00	0/0.27	2/2.55	0/0.41
POLY-3 PERCENT (g)	0%	0%	78.4%	0%
TERMINAL (d)	0/1 (0%)	0/0 (0%)	1/1 (100%)	0/0 (0%)
FIRST INCIDENCE	---	---	677	---
STATISTICAL TESTS				
POLY 3	P=0.565	(e)	P=0.433	(e)
POLY 1.5	P=0.739	(e)	P=0.468	(e)
POLY 6	P=0.265	(e)	P=0.359	(e)
COCH-ARM / FISHERS	P=0.790N	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.530	(e)	P=0.099	(e)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spleen				
Hematopoietic Cell Proliferation				
LESION RATES				
OVERALL (a)	15/50 (30%)	10/47 (21%)	11/48 (23%)	24/48 (50%)
POLY-3 RATE (b)	15/44.64	10/44.04	11/46.03	24/33.77
POLY-3 PERCENT (g)	33.6%	22.7%	23.9%	71.1%
TERMINAL (d)	8/33 (24%)	4/35 (11%)	5/36 (14%)	0/0 (0%)
FIRST INCIDENCE	589	568	563	432
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.182N	P=0.215N	P<0.001**
POLY 1.5	P<0.001**	P=0.193N	P=0.240N	P=0.005**
POLY 6	P<0.001**	P=0.168N	P=0.191N	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P=0.227N	P=0.286N	P=0.034*
MAX-ISO-POLY-3	P<0.001**	P=0.129N	P=0.160N	P<0.001**

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spleen Pigmentation				
LESION RATES				
OVERALL (a)	35/50 (70%)	26/47 (55%)	28/48 (58%)	31/48 (65%)
POLY-3 RATE (b)	35/46.29	26/43.74	28/45.33	31/37.51
POLY-3 PERCENT (g)	75.6%	59.4%	61.8%	82.6%
TERMINAL (d)	27/33 (82%)	22/35 (63%)	24/36 (67%)	0/0 (0%)
FIRST INCIDENCE	438	473	598	515
STATISTICAL TESTS				
POLY 3	P=0.074	P=0.071N	P=0.108N	P=0.281
POLY 1.5	P=0.206	P=0.071N	P=0.123N	P=0.569
POLY 6	P=0.016*	P=0.069N	P=0.092N	P=0.051
COCH-ARM / FISHERS	P=0.477	P=0.099N	P=0.160N	P=0.361N
MAX-ISO-POLY-3	P=0.094	P=0.046N*	P=0.070N	P=0.210

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Spleen: Lymphoid Follicle Atrophy

LESION RATES

OVERALL (a)	2/50 (4%)	1/47 (2%)	3/48 (6%)	1/48 (2%)
POLY-3 RATE (b)	2/44.33	1/42.52	3/44.48	1/19.89
POLY-3 PERCENT (g)	4.5%	2.4%	6.7%	5%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	2/36 (6%)	0/0 (0%)
FIRST INCIDENCE	340	590	677	432

STATISTICAL TESTS

POLY 3	P=0.392	P=0.515N	P=0.502	P=0.683
POLY 1.5	P=0.572	P=0.516N	P=0.493	P=0.636N
POLY 6	P=0.277	P=0.510N	P=0.513	P=0.506
COCH-ARM / FISHERS	P=0.487N	P=0.523N	P=0.480	P=0.515N
MAX-ISO-POLY-3	P=0.599	P=0.294N	P=0.327	P=0.475

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Spleen: Lymphoid Follicle
Hyperplasia

LESION RATES

OVERALL (a)	13/50 (26%)	20/47 (43%)	7/48 (15%)	21/48 (44%)
POLY-3 RATE (b)	13/43.38	20/42.22	7/44.28	21/31.49
POLY-3 PERCENT (g)	30%	47.4%	15.8%	66.7%
TERMINAL (d)	12/33 (36%)	19/35 (54%)	7/36 (19%)	0/0 (0%)
FIRST INCIDENCE	697	684	729 (T)	535

STATISTICAL TESTS

POLY 3	P=0.011*	P=0.071	P=0.090N	P<0.001**
POLY 1.5	P=0.032*	P=0.072	P=0.102N	P=0.008**
POLY 6	P=0.003**	P=0.075	P=0.078N	P<0.001**
COCH-ARM / FISHERS	P=0.110	P=0.066	P=0.125N	P=0.051
MAX-ISO-POLY-3	P=0.004**	P=0.045*	P=0.059N	P<0.001**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Spleen: Lymphoid Follicle Hyperplasia Focal				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/47 (0%)	0/48 (0%)	0/48 (0%)
POLY-3 RATE (b)	2/43.26	0/42.05	0/44.28	0/19.10
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	2/33 (6%)	0/35 (0%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.270N	P=0.243N	P=0.232N	P=0.440N
POLY 1.5	P=0.299N	P=0.245N	P=0.237N	P=0.337N
POLY 6	P=0.299N	P=0.240N	P=0.226N	P=0.586N
COCH-ARM / FISHERS	P=0.291N	P=0.263N	P=0.258N	P=0.258N
MAX-ISO-POLY-3	P=0.304N	P=0.079N	P=0.078N	P=0.261N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Edema				
LESION RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	1/43.72	0/44.47	0/45.67	0/19.47
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	593	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Erosion				
LESION RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	3/49 (6%)
POLY-3 RATE (b)	0/43.26	1/44.47	2/45.83	3/21.27
POLY-3 PERCENT (g)	0%	2.3%	4.4%	14.1%
TERMINAL (d)	0/33 (0%)	1/35 (3%)	1/37 (3%)	0/0 (0%)
FIRST INCIDENCE	---	729 (T)	688	535
STATISTICAL TESTS				
POLY 3	P=0.020*	P=0.506	P=0.250	P=0.041*
POLY 1.5	P=0.041*	P=0.505	P=0.245	P=0.068
POLY 6	P=0.025*	P=0.507	P=0.256	P=0.022*
COCH-ARM / FISHERS	P=0.089	P=0.500	P=0.247	P=0.117
MAX-ISO-POLY-3	P=0.034*	P=0.165	P=0.089	P=0.034*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Fibrosis				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.67	0/19.47
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Foreign Body				
LESION RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/43.26	0/44.47	0/45.67	0/19.47
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Inflammation				
LESION RATES				
OVERALL (a)	5/50 (10%)	3/50 (6%)	5/50 (10%)	6/49 (12%)
POLY-3 RATE (b)	5/44.64	3/45.26	5/45.85	6/23.02
POLY-3 PERCENT (g)	11.2%	6.6%	10.9%	26.1%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	587	634	688	535
STATISTICAL TESTS				
POLY 3	P=0.057	P=0.349N	P=0.614N	P=0.130
POLY 1.5	P=0.120	P=0.347N	P=0.618N	P=0.276
POLY 6	P=0.041*	P=0.350N	P=0.611N	P=0.034*
COCH-ARM / FISHERS	P=0.276	P=0.357N	P=0.630N	P=0.486
MAX-ISO-POLY-3	P=0.093	P=0.226N	P=0.481N	P=0.124

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Inflammation Chronic				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/43.43	0/44.47	0/45.67	0/19.47
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	683	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.268N	P=0.232N	P=0.226N	P=0.436N
POLY 1.5	P=0.298N	P=0.232N	P=0.230N	P=0.333N
POLY 6	P=0.294N	P=0.231N	P=0.222N	P=0.584N
COCH-ARM / FISHERS	P=0.292N	P=0.247N	P=0.247N	P=0.253N
MAX-ISO-POLY-3	P=0.296N	P=0.076N	P=0.076N	P=0.259N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach Ulcer				
LESION RATES				
OVERALL (a)	5/50 (10%)	3/50 (6%)	1/50 (2%)	1/49 (2%)
POLY-3 RATE (b)	5/45.07	3/45.45	1/45.69	1/20.16
POLY-3 PERCENT (g)	11.1%	6.6%	2.2%	5%
TERMINAL (d)	1/33 (3%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	340	568	726	496
STATISTICAL TESTS				
POLY 3	P=0.194N	P=0.352N	P=0.098N	P=0.388N
POLY 1.5	P=0.167N	P=0.350N	P=0.100N	P=0.223N
POLY 6	P=0.186N	P=0.350N	P=0.096N	P=0.639N
COCH-ARM / FISHERS	P=0.105N	P=0.357N	P=0.102N	P=0.107N
MAX-ISO-POLY-3	P=0.319N	P=0.228N	P=0.044N*	P=0.297N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Forestomach: Epithelium Hyperplasia				
LESION RATES				
OVERALL (a)	9/50 (18%)	5/50 (10%)	6/50 (12%)	16/49 (33%)
POLY-3 RATE (b)	9/45.59	5/45.26	6/45.83	16/29.04
POLY-3 PERCENT (g)	19.7%	11.1%	13.1%	55.1%
TERMINAL (d)	3/33 (9%)	2/35 (6%)	5/37 (14%)	0/0 (0%)
FIRST INCIDENCE	340	634	688	496
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.196N	P=0.283N	P<0.001**
POLY 1.5	P<0.001**	P=0.191N	P=0.284N	P=0.012*
POLY 6	P<0.001**	P=0.199N	P=0.283N	P<0.001**
COCH-ARM / FISHERS	P=0.004**	P=0.194N	P=0.288N	P=0.074
MAX-ISO-POLY-3	P<0.001**	P=0.127N	P=0.197N	P=0.003**

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Glandular Erosion				
LESION RATES				
OVERALL (a)	1/49 (2%)	0/47 (0%)	0/47 (0%)	1/48 (2%)
POLY-3 RATE (b)	1/42.61	0/42.31	0/43.45	1/19.79
POLY-3 PERCENT (g)	2.4%	0%	0%	5.1%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	684	---	---	496
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Stomach, Glandular
Inflammation

LESION RATES

OVERALL (a)	0/49 (0%)	0/47 (0%)	0/47 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/42.43	0/42.31	0/43.45	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Glandular Mineralization				
LESION RATES				
OVERALL (a)	5/49 (10%)	6/47 (13%)	6/47 (13%)	1/48 (2%)
POLY-3 RATE (b)	5/43.68	6/43.73	6/44.16	1/19.69
POLY-3 PERCENT (g)	11.5%	13.7%	13.6%	5.1%
TERMINAL (d)	3/33 (9%)	2/35 (6%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	340	568	598	542
STATISTICAL TESTS				
POLY 3	P=0.352N	P=0.501	P=0.508	P=0.384N
POLY 1.5	P=0.174N	P=0.492	P=0.492	P=0.222N
POLY 6	P=0.560	P=0.519	P=0.529	P=0.636N
COCH-ARM / FISHERS	P=0.052N	P=0.470	P=0.470	P=0.107N
MAX-ISO-POLY-3	P=0.471N	P=0.375	P=0.382	P=0.294N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Glandular Ulcer				
LESION RATES				
OVERALL (a)	0/49 (0%)	1/47 (2%)	1/47 (2%)	0/48 (0%)
POLY-3 RATE (b)	0/42.43	1/42.46	1/43.65	0/19.10
POLY-3 PERCENT (g)	0%	2.4%	2.3%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	690	677	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Stomach, Glandular: Glands				
Ectasia Focal				
LESION RATES				
OVERALL (a)	4/49 (8%)	3/47 (6%)	4/47 (9%)	1/48 (2%)
POLY-3 RATE (b)	4/42.71	3/42.31	4/43.65	1/19.69
POLY-3 PERCENT (g)	9.4%	7.1%	9.2%	5.1%
TERMINAL (d)	3/33 (9%)	3/35 (9%)	3/37 (8%)	0/0 (0%)
FIRST INCIDENCE	656	729 (T)	677	542
STATISTICAL TESTS				
POLY 3	P=0.471N	P=0.505N	P=0.632N	P=0.473N
POLY 1.5	P=0.317N	P=0.507N	P=0.642	P=0.314N
POLY 6	P=0.538	P=0.501N	P=0.617N	P=0.617
COCH-ARM / FISHERS	P=0.159N	P=0.524N	P=0.619	P=0.187N
MAX-ISO-POLY-3	P=0.569N	P=0.352N	P=0.487N	P=0.345N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thymus Atrophy				
LESION RATES				
OVERALL (a)	25/48 (52%)	22/45 (49%)	26/46 (57%)	13/46 (28%)
POLY-3 RATE (b)	25/45.56	22/43.76	26/44.81	13/26.56
POLY-3 PERCENT (g)	54.9%	50.3%	58%	48.9%
TERMINAL (d)	15/32 (47%)	12/33 (36%)	18/34 (53%)	0/0 (0%)
FIRST INCIDENCE	340	421	3	432
STATISTICAL TESTS				
POLY 3	P=0.484N	P=0.411N	P=0.464	P=0.404N
POLY 1.5	P=0.132N	P=0.419N	P=0.459	P=0.108N
POLY 6	P=0.163	P=0.389N	P=0.476	P=0.248
COCH-ARM / FISHERS	P=0.008N**	P=0.460N	P=0.411	P=0.016N*
MAX-ISO-POLY-3	P=0.565N	P=0.332N	P=0.380	P=0.343N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thymus Cyst				
LESION RATES				
OVERALL (a)	8/48 (17%)	6/45 (13%)	6/46 (13%)	2/46 (4%)
POLY-3 RATE (b)	8/42.82	6/40.86	6/41.98	2/19.57
POLY-3 PERCENT (g)	18.7%	14.7%	14.3%	10.2%
TERMINAL (d)	4/32 (13%)	5/33 (15%)	4/34 (12%)	0/0 (0%)
FIRST INCIDENCE	589	618	688	542
STATISTICAL TESTS				
POLY 3	P=0.304N	P=0.422N	P=0.401N	P=0.337N
POLY 1.5	P=0.158N	P=0.420N	P=0.406N	P=0.152N
POLY 6	P=0.505N	P=0.425N	P=0.398N	P=0.576
COCH-ARM / FISHERS	P=0.048N*	P=0.438N	P=0.420N	P=0.052N
MAX-ISO-POLY-3	P=0.473N	P=0.314N	P=0.294N	P=0.280N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thymus				
Hyperplasia Lymphoid				
LESION RATES				
OVERALL (a)	16/48 (33%)	16/45 (36%)	9/46 (20%)	10/46 (22%)
POLY-3 RATE (b)	16/41.57	16/40.98	9/41.69	10/24.28
POLY-3 PERCENT (g)	38.5%	39.1%	21.6%	41.2%
TERMINAL (d)	15/32 (47%)	14/33 (42%)	9/34 (27%)	0/0 (0%)
FIRST INCIDENCE	680	634	729 (T)	542
STATISTICAL TESTS				
POLY 3	P=0.440N	P=0.569	P=0.071N	P=0.518
POLY 1.5	P=0.256N	P=0.552	P=0.081N	P=0.380N
POLY 6	P=0.493	P=0.586N	P=0.062N	P=0.139
COCH-ARM / FISHERS	P=0.087N	P=0.497	P=0.101N	P=0.153N
MAX-ISO-POLY-3	P=0.438N	P=0.478	P=0.045N*	P=0.429

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thymus				
Necrosis Lymphoid				
LESION RATES				
OVERALL (a)	2/48 (4%)	1/45 (2%)	1/46 (2%)	0/46 (0%)
POLY-3 RATE (b)	2/42.36	1/40.94	1/42.69	0/18.39
POLY-3 PERCENT (g)	4.7%	2.4%	2.3%	0%
TERMINAL (d)	0/32 (0%)	0/33 (0%)	0/34 (0%)	0/0 (0%)
FIRST INCIDENCE	579	590	3	---
STATISTICAL TESTS				
POLY 3	P=0.333N	P=0.512N	P=0.497N	P=0.444N
POLY 1.5	P=0.280N	P=0.513N	P=0.500N	P=0.340N
POLY 6	P=0.474N	P=0.510N	P=0.495N	P=0.589N
COCH-ARM / FISHERS	P=0.210N	P=0.524N	P=0.516N	P=0.258N
MAX-ISO-POLY-3	P=0.433N	P=0.291N	P=0.281N	P=0.265N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thyroid Gland: Follicle Cyst				
LESION RATES				
OVERALL (a)	2/50 (4%)	1/49 (2%)	0/48 (0%)	0/47 (0%)
POLY-3 RATE (b)	2/43.26	1/43.54	0/44.18	0/18.79
POLY-3 PERCENT (g)	4.6%	2.3%	0%	0%
TERMINAL (d)	2/33 (6%)	0/34 (0%)	0/36 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	712	---	---
STATISTICAL TESTS				
POLY 3	P=0.197N	P=0.498N	P=0.232N	P=0.443N
POLY 1.5	P=0.212N	P=0.498N	P=0.238N	P=0.342N
POLY 6	P=0.207N	P=0.496N	P=0.226N	P=0.588N
COCH-ARM / FISHERS	P=0.194N	P=0.508N	P=0.258N	P=0.263N
MAX-ISO-POLY-3	P=0.324N	P=0.280N	P=0.078N	P=0.264N

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thyroid Gland: Follicle Degeneration				
LESION RATES				
OVERALL (a)	34/50 (68%)	28/49 (57%)	26/48 (54%)	11/47 (23%)
POLY-3 RATE (b)	34/46.70	28/46.65	26/46.55	11/25.47
POLY-3 PERCENT (g)	72.8%	60%	55.9%	43.2%
TERMINAL (d)	22/33 (67%)	21/34 (62%)	18/36 (50%)	0/0 (0%)
FIRST INCIDENCE	438	421	535	432
STATISTICAL TESTS				
POLY 3	P=0.023N*	P=0.133N	P=0.065N	P=0.008N**
POLY 1.5	P<0.001N**	P=0.132N	P=0.078N	P<0.001N**
POLY 6	P=0.213N	P=0.146N	P=0.054N	P=0.366N
COCH-ARM / FISHERS	P<0.001N**	P=0.182N	P=0.115N	P<0.001N**
MAX-ISO-POLY-3	P=0.038N*	P=0.091N	P=0.042N*	P=0.015N*

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Thyroid Gland: Follicle Hypertrophy				
LESION RATES				
OVERALL (a)	24/50 (48%)	31/49 (63%)	37/48 (77%)	42/47 (89%)
POLY-3 RATE (b)	24/46.47	31/47.00	37/46.90	42/43.89
POLY-3 PERCENT (g)	51.7%	66%	78.9%	95.7%
TERMINAL (d)	17/33 (52%)	21/34 (62%)	29/36 (81%)	0/0 (0%)
FIRST INCIDENCE	4	473	3	432
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.111	P=0.003**	P<0.001**
POLY 1.5	P<0.001**	P=0.102	P=0.003**	P<0.001**
POLY 6	P<0.001**	P=0.129	P=0.005**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.092	P=0.003**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.077	P=0.002**	P<0.001**

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Urethra Inflammation Acute				
LESION RATES				
OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG

Urethra: Bulbourethral Gland
Necrosis

LESION RATES

OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---

STATISTICAL TESTS

POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Urinary Bladder Hemorrhage				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/42.72	0/44.47	0/45.28	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Urinary Bladder Inflammation Acute				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/42.72	0/44.47	0/45.28	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Urinary Bladder Necrosis				
LESION RATES				
OVERALL (a)	0/49 (0%)	0/50 (0%)	0/49 (0%)	0/48 (0%)
POLY-3 RATE (b)	0/42.72	0/44.47	0/45.28	0/19.10
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/33 (0%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Uterus Cyst				
LESION RATES				
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/43.26	0/44.47	0/45.67	0/19.47
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	2/33 (6%)	0/35 (0%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
STATISTICAL TESTS				
POLY 3	P=0.269N	P=0.231N	P=0.225N	P=0.435N
POLY 1.5	P=0.299N	P=0.232N	P=0.230N	P=0.332N
POLY 6	P=0.295N	P=0.229N	P=0.220N	P=0.583N
COCH-ARM / FISHERS	P=0.292N	P=0.247N	P=0.247N	P=0.253N
MAX-ISO-POLY-3	P=0.295N	P=0.076N	P=0.076N	P=0.258N

Experiment Number: 20209 - 04
 Test Type: CHRONIC
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
 Time Report Requested: 08:48:44
 First Dose M/F: 02/25/08 / 02/25/08
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Uterus Hemorrhage				
LESION RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	1/43.26	2/44.53	0/45.67	0/19.47
POLY-3 PERCENT (g)	2.3%	4.5%	0%	0%
TERMINAL (d)	1/33 (3%)	1/35 (3%)	0/37 (0%)	0/0 (0%)
FIRST INCIDENCE	729 (T)	715	---	---
STATISTICAL TESTS				
POLY 3	P=0.212N	P=0.510	P=0.489N	P=0.639N
POLY 1.5	P=0.221N	P=0.509	P=0.493N	P=0.575N
POLY 6	P=0.233N	P=0.512	P=0.484N	P=0.714N
COCH-ARM / FISHERS	P=0.201N	P=0.500	P=0.500N	P=0.505N
MAX-ISO-POLY-3	P=0.348N	P=0.292	P=0.158N	P=0.325N

Experiment Number: 20209 - 04
Test Type: CHRONIC
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
Pentabromodiphenyl oxide (technical) (DE 71)
CAS Number: 32534-81-9

Date Report Requested: 09/10/2014
Time Report Requested: 08:48:44
First Dose M/F: 02/25/08 / 02/25/08
Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Uterus				
Hyperplasia Cystic				
LESION RATES				
OVERALL (a)	45/50 (90%)	47/50 (94%)	46/50 (92%)	43/49 (88%)
POLY-3 RATE (b)	45/48.46	47/49.07	46/48.20	43/44.93
POLY-3 PERCENT (g)	92.9%	95.8%	95.4%	95.7%
TERMINAL (d)	33/33 (100%)	34/35 (97%)	36/37 (97%)	0/0 (0%)
FIRST INCIDENCE	4	421	563	496
STATISTICAL TESTS				
POLY 3	P=0.465	P=0.417	P=0.452	P=0.428
POLY 1.5	P=0.547N	P=0.389	P=0.414	P=0.591
POLY 6	P=0.256	P=0.474	P=0.522	P=0.255
COCH-ARM / FISHERS	P=0.266N	P=0.357	P=0.500	P=0.486N
MAX-ISO-POLY-3	P=0.391	P=0.244	P=0.275	P=0.240

Experiment Number: 20209 - 04

Test Type: CHRONIC

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 09/10/2014

Time Report Requested: 08:48:44

First Dose M/F: 02/25/08 / 02/25/08

Lab: SRI

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (e) Value of statistic cannot be computed.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (n) No statistics are calculated if all dose groups have fewer than two tumors.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***